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Emerging adulthood (18 to 29 years old) is a critical age group in relation to the Human 
Immunodeficiency Virus (HIV) epidemic and to mental health. A major public health concern 
globally, in management of HIV, is that emerging adults have suboptimal antiretroviral 
therapy (ART) adherence, yet they are the largest group initiating ART. In addition, common 
mental disorders (CMDs), including depression and anxiety have their peak incidence during 
this period and they have been found to increase risk of non-adherence to ART.  Those with 
CMDs may have different types of barriers than those without CMDs. Furthermore, those with 
CMDs might be more likely to have a greater number of barriers to adherence than those 
without because of the way symptoms of CMDs impact on memory, problem solving skills 
and concentration.  
Aims  
The main aim of this study was to describe barriers to adherence to ART in emerging adults 
living with HIV with probable CMDs (i.e. depression and/or anxiety) and accessing HIV 
treatment at a government clinic in Harare, Zimbabwe, compared to emerging adults living 
with HIV without probable CMDs. The specific objectives were: 
a. to determine the prevalence of probable CMDs among emerging adults living with HIV 
b. to describe the prevalence, severity and common barriers to ART adherence, 
measured using the 22-item Barriers to Adherence (BARTA scale) in emerging adults 
living with HIV with probable CMDs and to compare this with those without probable 
CMDs.  
Methods 
A representative sample of 223 emerging adults aged 18 to 29 years were recruited in a cross-
sectional study using the random sampling technique. The Patient Health Questionnaire-9 
(PHQ-9), Generalized Anxiety Disorder-7 (GAD-7) and Barriers to Adherence Scale (BARTA 
scale) were used to assess probable depression, probable anxiety and barriers to adherence 
respectively. 
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Data Analysis  
Univariate Descriptive statistics were used to describe the socio-demographic, prevalence of 
probable CMDs, prevalence of barriers to adherence, overall median of total BARTA score 
(severity of barriers to ART adherence) for the whole sample and overall median number of 
barriers to ART adherence for the whole sample.  
Chi-square analyses were used to compare the prevalence of barriers (no barrier vs. at least 
one) between participants with and without probable CMDs.  
Non-parametric Wilcoxon rank-sum tests and Kruskal Wallis tests (for variables with more 
than two categories) were used to  
I. Compare the number of barriers to ART adherence between participants with and 
without a probable CMDs; 
II. Compare the severity of barriers to ART adherence between participants with and 
without probable CMDs, using overall scores on the BARTA scale  
III.  Assess the relationship between demographic variables, HIV related variables, 
Substance Use Disorders (SUD) and total BARTA scores. 
Variables which were significantly associated with BARTA scores were entered into a negative 
binomial regression model, to assess the relationship between CMDs and severity of barriers 
to ART adherence, this time controlling for possible demographic confounding factors.  
Results 
The prevalence of probable CMDs (i.e. probable depression and/or probable anxiety) was 
33.2%. Specifically, 31.8% had probable depression and 16.1% had probable anxiety.   Results 
showed that 76.2 % of the sample experienced at least one barrier to ART adherence and that 
94.5% of those with CMDs experienced at least one barrier to adherence compared to 67.1% 
of those without CMDs (p>0.001).   
We found a significant difference (U=-7.209, p<0.001) between the number of barriers 
experienced by participants with and without CMDs: participants with a CMD reported a 
greater number of barriers (median (md) =5, IQR=3-7) compared to those without CMDs (md= 
1, IQR=0-4). 
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A statistically significant difference was also found in total BARTA scores between participants 
with and without CMDs: participants with a CMD reported a greater BARTA score (md=7, 
IQR=4-12) compared to those without a CMD (md= 2, IQR=0-4; U=-7.415, p<0.001). 
The most frequent barriers reported by emerging adults living with HIV with probable CMDs 
were ‘forgetting’ (68.0%), ‘thinking too much’ (49.0%), ‘having to take ART in front of others’ 
(41.0%) and ‘not having a reminder’ (39.0%). The most frequent barriers for emerging adults 
living with HIV without probable CMDs were ‘forgetting’ (30%), ‘not having medications with 
them’ (21%), ‘not wanting others to know their status’ (20%) and ‘not having a reminder’ 
(19%). Although ‘forgetting’ and ‘not having a reminder’ were among the top barriers in both 
groups, those with probable CMDs reported them more frequently. 
Conclusion 
This study has shown that firstly, CMDs and barriers to ART adherence are prevalent among 
emerging adults living with HIV. Secondly, emerging adults living with HIV with probable 
CMDs experience a high number of barriers to ART adherence and more severely than those 
without probable CMDs. Finally, emerging adults with CMDs reported barriers such as 
forgetting and not having a reminder more frequently than those without CMDs. This calls for 
routine screening for probable CMDs and barriers to ART adherence in HIV clinics. 
Furthermore, there is need to come up with tailored psychological interventions that can 
simultaneously treat CMDs and reduce barriers to ART adherence among emerging adults 
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CHAPTER 1: INTRODUCTION 
The study focuses on Common Mental Disorders (CMDs) and barriers to antiretroviral therapy 
(ART) adherence among emerging adults living with Human Immunodeficiency Virus (HIV) at 
an HIV clinic in Harare, Zimbabwe. This chapter presents the background of the study, 
statement of the problem, significance of the study, research question, aims, and hypothesis.  
Background to the study 
Emerging adulthood is the period between adolescence and entry into adulthood lasting from 
18 years to 29 years (Arnett & Padilla-Walker, 2015). This is a critical age group both in relation 
to the HIV epidemic and mental health. An estimated 3.9 million individuals aged 15 to 24 
years are living with HIV globally (UNAIDS, 2017). Nearly 85 percent of individuals between 
the ages of 15 to 24 years living with HIV reside in Sub-Saharan Africa (SSA) (UNAIDS, 2017; 
UNICEF, 2016). In Zimbabwe - a country in SSA, 5.5% and 10.9% of emerging adults aged 20-
24 years and 25-29 years respectively are living with HIV (Ministry of Health and Child Care 
(MOHCC) Zimbabwe., 2017).  
New HIV infection rates remain high among emerging adults worldwide. In 2014, emerging 
adults aged 15 to 24 years and 25 to 34 years represented approximately 34.0% and 32.0% of 
all new infections in adults respectively (UNAIDS, 2015). Most of these new diagnoses 
occurred among young females aged 15 to 24 years (370 000) compared to (280 000) young 
males (UNAIDS, 2015). Young women are at high risk of new HIV infections because of their 
biological make up and by engaging in sexual relationships with older men (intergenerational 
sex), and engaging in sex in exchange for gifts (transactional sex) (Idele et al., 2014; Kilburn et 
al., 2018; Somse et al., 2017).  
 
In addition, mental disorders are also common in this age group, especially depression and 
anxiety (Institute of Medicine and National Research Council, 2013; Patel et al., 2007). It is 
estimated that 20.0% of lifetime prevalence of mental disorders like depression, begin to 
appear by the age of 14 years and 75.0% by the age of 24 years (Martinez et al., 2009b). In 
2015, depression affected approximately 6.8% of young females and 5.5% of young males 
while anxiety affected nearly 5.5% and 3.5% of young females and males aged 20 to 24 years 
respectively,  worldwide (WHO, 2017). Despite emerging adults being at risk of common 
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mental disorders, depression and anxiety disorders are usually undiagnosed and untreated 
among this age group due to lack of recognition, fear of stigma, and limited mental health 
resources (Davey & Mcgorry, 2019; Smith, 2014).   A systematic review conducted in Africa, 
reported that people living with HIV (PLWH) are at increased risk of CMDs compared to those 
who are HIV negative (Brandt, 2009). A study conducted in Zimbabwe among adults aged 18 
years and above found a high prevalence rate (68.5%) of depression among PLWH compared 
to 47.2% among those who were HIV negative (Chibanda, Cowan, et al., 2016). 
Substance use disorders (SUDs), which may co-occur with CMDs in PLWH, are also at peak 
prevalence during emerging adulthood (Gammarel et al., 2016). Many people start using 
substances during adolescence and reach peak prevalence during emerging adulthood (Wisk 
& Weitzman, 2016). The most common substances that are used by emerging adults include 
alcohol, tobacco and marijuana (Wisk & Weitzman, 2016). Prior studies from high-income 
countries (HICs) have shown high rates of SUDs among emerging adults living with HIV. In 
HICs, the estimated prevalence rate of alcohol use ranges from 19.0% to 87.0%, and of other 
substances such as tobacco and marijuana ranges from 20.4% to 45.5% (Conner et al., 2013; 
Gamarel et al., 2018; Martinez et al., 2009b; Nichols et al., 2014; Thompson et al., 2018). Also, 
a systematic review conducted in SSA found that alcohol and drug use was more prevalent 
among emerging adults living with HIV compared to their uninfected peers (Ssewanyana et 
al., 2018). The prevalence of alcohol use among emerging adults living with HIV residing in 
SSA ranges from 3.8% to 35.9% while the prevalence of other substances ranged from 4.4% 
to 46% (Bultum et al., 2018; Jewkes et al., 2006; Kiunyu, 2015; Kuteesa et al., 2020; Mabunda 
et al., 2019; Test et al., 2012). Emerging adults living with HIV may use marijuana and alcohol 
as a coping strategy for living with a chronic disease (Bruce et al., 2013). This could be one of 
the reasons why the rate of substance use is high among this population. While the 
prevalences from these different studies show that substance use is common among this 
population, the rates vary widely. This could be because of different age ranges and different 
tools that assess alcohol and substance use.  
Emerging adults with CMDs are at increased risk of substance use compared to those without 
CMDs as they may use them to deal with the symptoms of CMDs (Mckenzie et al., 2011). 
While PLWH may use substances as a coping strategy, substance use has several negative 
consequences, such as failure to meet daily routines at school, not completing homework and 
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may lead to clinically significant functional impairment and health problems (Bough & Pollock, 
2018; Hasin et al., 2014; World Health Organization, 2017). 
CMDs have a great impact on HIV treatment as they may contribute to low rates of 
engagement in care and non-adherence to ART among PLWH (Tesfaw et al., 2016). Studies 
from both HIC and LMICs found that PLWH with symptoms of CMDs are less likely to achieve 
good adherence to ART compared to those without CMDs (Gonzalez, Batchelder, et al., 2011; 
Kong et al., 2012; Mayston et al., 2012; Memiah et al., 2014; Moraes & Casseb, 2017; 
Nakimuli-Mpungu et al., 2012; Uthman et al., 2014). However, other studies found no 
association between poor ART adherence and CMDs among PLWH world-wide (Binagwaho et 
al., 2016; Fawzi et al., 2016; Kitshoff et al., 2012; Kyser et al., 2011). Different findings could 
be attributed to tools used to measure CMDs and ART adherence as well as different study 
population. Furthermore, some studies did not use validated tools to measure CMDs and ART 
adherence (Kitshoff et al., 2012; Springer et al., 2012).While CMDs have an impact on 
adherence, very few clinics routinely screen for these mental conditions (Dawson-Rose et al., 
2018). Poor adherence to ART may have serious consequences for the patient including falling 
CD4 counts, developing drug resistance, limited future treatment options, disease 
progression and more hospitalisation (Ehlers & Tshisuyi, 2015). Failure to adhere to 
medication does not only affect the patient but also the healthcare system and the 
government as the virus builds resistance, thereby requiring drugs that are more 
sophisticated and expensive for the government to purchase (Gellad et al., 2009). Due to this, 
it is of great importance to examine the prevalence of CMDs among emerging adults living 
with HIV in Zimbabwe where a high rate of CMDs (68.5%) has been recorded among adults 
aged 18 years and above (Chibanda, Cowan, et al., 2016).  
Barriers to ART adherence among HIV infected emerging adults 
One of the major public health concerns globally is that emerging adults have suboptimal ART 
adherence, yet they are the largest group of people initiating ART (MacDonell et al., 2013). 
Studies from African countries have found that 14.0 to 29.0% of emerging adults living with 
HIV have poor adherence to ART (Gebrezgabher et al., 2017; Letta et al., 2015; Mukui et al., 
2016). Furthermore, it has been reported in Zimbabwe that emerging adults living with HIV 
have lower rates of viral suppression  (48.6%) among females aged 15 to 24 years, 40.2% and 
37% among males aged 25 to 34 years) compared to older adults with a viral suppression rate 
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of 78.7% and 71.1% among females aged 45 to 54 years and males aged 55 years and older 
respectively (ZIMPHIA, 2016). For this and other reasons to be discussed below, it is 
imperative to examine barriers that hinder adherence among this critical age group. 
A barrier to medication adherence can be defined as any factor that can make it difficult to 
take medication or that can contribute to non-adherence behaviour (Engler et al., 2018). 
Barriers can be broadly categorised into patient-related barriers, interpersonal barriers and 
structural barriers (Davis et al., 2018). These categorises will be explained in detail in the next 
chapter. Although the Zimbabwean government has dealt with some of the structural barriers 
to ART by providing ART at no cost to the HIV patients and making it accessible, adherence to 
HIV medication remains a challenge and PLWH still face barriers to taking ART (Apollo et al., 
2013; Rudy, Murphy, Harris, Muenz, & Ellen, 2010). A recent study conducted at an HIV clinic 
in Harare, Zimbabwe, among adults aged 18 and above reported that 48.0% of adults living 
with HIV experienced at least one barrier to ART (Croome et al., 2018).  
A number of barriers have previously been found to be associated with decreased adherence 
to ART.  The most frequently reported barriers among adults are patient-related barriers 
which include forgetting, lack of adequate food, fear of side effects and being away from 
home (Croome et al., 2018; Shubber et al., 2016). However, few studies have examined the 
most common barriers to ART adherence among emerging adults living with HIV in Zimbabwe 
or in other countries in SSA. It is critical to examine barriers to ART adherence among 
emerging adults living with HIV in SSA particularly in Zimbabwe for a number of reasons 
discussed below.  
Firstly, as mentioned above,  emerging adults have poor adherence to ART compared to older 
adults (35 years and above) (Heestermans et al., 2016; Memiah et al., 2014). This could be 
due to transition of care from child to adult HIV services which involves major changes, for 
example change in healthcare providers, changing of model of care and taking responsibility 
of their own health (Dahourou et al., 2017). Also it could be due to increased risk taking, and 
decreased parental control and guidance (MacDonell et al., 2013). As stated above, poor 
adherence to ART has several consequences including increased hospitalisation, decreased 
quality of life, and increased mortality rates (Ehlers & Tshisuyi, 2015). In low and middle 
income countries (LMICs) like Zimbabwe where ART options available are limited, it is 
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imperative for emerging adults living with HIV to maintain good adherence to first line 
medication in order to have long-lasting treatment benefits (Coetzee et al., 2015). For 
emerging adults to maintain first or second line medication, early identification of barriers to 
ART adherence could be helpful, not only among those with high viral load but also among 
those with viral suppression. Early identification of barriers to ART adherence among those 
with viral suppression may allow intervention before this clinical indicator deteriorates 
(Engler et al., 2018). 
Secondly, emerging adults are at a developmental stage which is characterised by a shift from 
adolescence into adulthood (Arnett & Padilla-Walker, 2015). This stage involves a large 
number of changes, such as moving out of their parents’ home, limited parental control, 
increased risk taking, completing education, searching for stable employment and engaging 
in stable relationships that may lead into marriage (Arnett, 2003). During this stage, emerging 
adults may face stressors such as low educational achievement, inability to cope with peer 
pressure, and difficulties in finding employment (Arnett, Žukauskienė, Sugimura, & Since, 
2014). These stressors and the characteristics of this developmental stage may expose 
emerging adults to certain patient-related barriers to ART adherence more frequently than 
any other age group. Understanding the pattern and the most common barriers to ART 
adherence, among this particular age group, is critical as it may help to inform adherence-
counselling approaches. 
Common mental disorders and barriers to ART adherence 
CMDs are at their peak during emerging adulthood (Davey & Mcgorry, 2019; Whiteford et al., 
2015). HIV infected emerging adults are at higher risk of developing CMDs than those who 
are HIV negative, as they have the extra burden of taking ART every day at the same time and 
dealing with HIV related stigma and discrimination (Myer et al., 2009; UNAIDS, 2018).  
For HIV infected individuals, those with CMDs, may find adhering to ART more difficult 
compared to those without CMDs (Tlhajoane et al., 2017). This is because adherence to 
medications requires motivation, energy, and good cognitive functioning. The symptoms of 
CMDs, such as having negative thoughts, low mood, and poor concentration, may negatively 
affect ART adherence (Akincigila et al., 2011; Kidia et al., 2015b). These symptoms can make 
people with CMDs forgetful and having less interest in taking their medication which can 
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make them skip their medications (Kidia et al., 2015). It is therefore possible that these 
barriers can be more frequent among emerging adults with CMDs. It is important to 
determine which barriers to ART adherence are experienced more frequently by HIV infected 
emerging adults with CMDs than those without CMDs. Such findings will help to develop 
strategies that are tailored to treat CMDs and overcome barriers to ART simultaneously to 
improve adherence and ART outcomes. 
Knowledge gap 
While there are studies in SSA that focused on mental health and barriers to ART adherence 
among PLWH, we identified major gaps in the literature (Abas et al., 2017; Chibanda, Cowan, 
et al., 2016; Croome et al., 2017). Firstly, in Zimbabwe, mental health studies, have not 
specifically focused on the prevalence of CMDs among emerging adults living with HIV. 
Secondly, there are limited studies in SSA that examined common barriers to ART adherence 
among HIV infected emerging adults with and without CMDs particularly in Zimbabwe, where 
new HIV infections and suboptimal ART adherence rates are still high in this population. 
Finally, to my knowledge, there are no studies that compared barriers to ART adherence 
between HIV infected emerging adults with CMDs and HIV infected emerging adults without 
CMDs. It could be possible that these two groups experience barriers to ART adherence that 
are different. In order to fill in these gaps, this study focused on the prevalence of probable 
CMDs and describes barriers to ART adherence among HIV infected emerging adults with 
CMDs in comparison to those without CMDs. 
Significance of the study 
Although the results cannot be generalised, this additional information may help to 
understand the 
1. Prevalence of probable CMDs among emerging adults living with HIV. This will add to 
current evidence for the CMDs for the specific age group and point to the need for 
routine screening for CMDs in HIV clinics. 
2. Prevalence, severity and common barriers to ART adherence reported by emerging 
adults living with HIV with probable CMDs in comparison to those without probable 
CMDs. This will inform adherence counselling approaches and also point to the need 
for routine screening for barriers to ART in HIV clinics. Furthermore, the results may 
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guide future studies to come up with tailored adherence interventions  can that best 
promote and maintain adherence among this young generation. 
Aims 
The aim of this study was to describe barriers to ART adherence in emerging adults living with 
HIV with probable common mental disorders (i.e. depression and/or anxiety) compared to 
emerging adults living with HIV without probable common mental disorders accessing 
treatment at Parirenyatwa Centre of Excellence in Harare, Zimbabwe.   
  Objectives 
1. To determine the prevalence of probable common mental disorders among emerging 
adults living with HIV  
2. To describe the prevalence, number, type and severity of barriers to ART adherence, 
measured using the 22-item Barriers to ART adherence scale (BARTA scale) in 
emerging adults living with HIV with probable CMDs and to compare this with those 
without probable CMDs.  
Hypothesis 
1. Emerging adults living with HIV with probable common mental disorders have a 
greater number of barriers to ART adherence than those without probable common 
mental disorders 
2. Barriers to ART adherence are more severe (high total BARTA score) among emerging 
adults with probable common mental disorders than those without common mental 
disorders
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CHAPTER 2: LITERATURE REVIEW 
This chapter focuses on a review of the literature describing the prevalence of common 
mental disorders (CMDs) and barriers to antiretroviral therapy (ART) adherence among 
emerging adults living with Human Immunodeficiency Virus (HIV). The sections in this chapter 
are guided by the research aim and the objectives of the study. Finally, the knowledge gap, 
that the study intends to fill is identified.. 
Search strategy 
In order to review the literature, I was guided by the tools of systematic reviews. I used 
principles of using search terms to identify relevant papers, but I did not do a systematic 
checking of all databases to identify relevant articles, nor systematic checking of all papers 
identified to extract information. The databases I searched were PubMed, PMC, Science 
direct, Psychoinfo and Cochrane database from 1 February 2018 to 31 August 2019. Database 
searches included a variety of combinations of terms as shown in the table below (Table 1).  
The boolean operators have been used in the search terms to identify the literature. The 
search included publications from high, middle- and low-income countries and it was not 
restricted by date. 
Table 1: Illustrating the search strategy 
 Specific search terms 
Prevalence (((prevalence) OR rate) OR statistics) OR burden 
Common mental 
disorders 
(((common mental disorders) OR CMDs) OR depression) OR anxiety 
Barriers to ART adherence ((((barriers to antiretroviral therapy adherence) OR factors affecting 
adherence to ART) OR barriers to adherence to ARVs) OR barriers to ART 
adherence) OR barriers to HIV medication adherence 
Emerging adults (((((emerging adults living with HIV) OR HIV infected emerging adults) OR 
young adults living with HIV) OR HIV infected young adults) OR youth living 
with HIV) OR HIV infected youth 
The prevalence of 
common mental disorders 
and barriers to ART 
adherence among 
emerging adults living 
with HIV 
(((((((prevalence) OR rate) OR statistics) OR burden)) AND ((((common 
mental disorders) OR CMDs) OR depression) OR anxiety)) AND (((((barriers 
to antiretroviral therapy adherence) OR factors affecting adherence to ART) 
OR barriers to adherence to ARVs) OR barriers to ART adherence) OR barriers 
to HIV medication adherence)) AND ((((((emerging adults living with HIV) OR 
HIV infected emerging adults) OR young adults living with HIV) OR HIV 
infected young adults) OR youth living with HIV) OR HIV infected youth) 
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Inclusion and exclusion criteria 
The articles were selected based on the combination of the study aims and objectives.  
Articles were included if they focused on either;  
1. Prevalence of common mental disorders (i.e. depression and anxiety) among HIV 
infected individuals. Articles were included if they focused either on combined anxiety 
and depression or anxiety or depression only. Samples should have included HIV 
infected individuals with any of the ages between 18 to 29 years. Those with 
adolescents were included if the sample included those aged 18 years and above while 
those with adult populations were included if the sample included those aged 18 to 
29 years. 
2. Barriers to ART adherence among HIV infected individuals. Samples should have 
included HIV infected individuals with any of the ages between 18 to 29 years. Those 
with adolescents were included if the sample included those aged 18 years and above 
while those with adult population were included if the sample included those aged 18 
to 29 years. 
Articles that did not meet the inclusion criteria were removed based either on the review 
of the title, abstract or on the full article. Articles were excluded if they dealt with issues 
that were not related to the study aims and objectives such as major mental disorders 
(e.g. psychosis, schizophrenia and common mental disorders among the general 
population). Articles that were not written in English were also excluded. 
Number of articles found and data extraction 
 The search yielded 4847 articles using the search terms shown in Table 1 and 15 articles 
found from the reference list of the identified articles and grey literature were added. A total 
number of 4730 articles were excluded based upon irrelevant titles and abstracts. From the 
remaining 85 articles, 27 were found not to be relevant and were excluded. The remaining 58 
articles were reviewed to extract the relevant information as informed by the research aim 
and questions.(see the flow diagram below (fig 1) for illustration of the procedure).  
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Figure 1: A flow chart illustrating the process of article selection for the literature review 
Prevalence of Common mental disorders in HIV infected emerging adults 
The main purpose of this section is to review the literature I identified on the prevalence of 
common mental disorders (CMDs) among emerging adults living with HIV. Key terms are 
defined in the beginning of the section and these include common mental disorders, 
depression and anxiety. It is important to note that there are limited data on the prevalence 
of CMDs in emerging adults aged 18 to 29 years, so articles that included those slightly below 
the age of 18 and slightly above the age of 29 years were included in the review. 
Defining Common mental disorders 
Common mental disorders (CMDs) refer to two main mental health conditions - depressive 
disorders and anxiety disorders (WHO, 2017). These conditions were termed ‘common’ 
because they are highly prevalent in the population (WHO, 2017). Depression and anxiety 
normally begin during adolescence and are at their peak during emerging adulthood (Craske 
& Stein, 2016; Davey & Mcgorry, 2019).  
Defining depression 
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition  (DSM-5), 
depression is a mood disorder characterised by low mood, poor concentration, sadness, 
feeling of tiredness, loss of interest or pleasure, loss of appetite, feeling guilt or low self-worth 
and disturbed sleep (APA, 2013). These symptoms can impair one’s ability to perform daily 
activities such as work related, school related and household duties (World Health 
Organization, 2017).  For one to be diagnosed with depression, these symptoms should be 
present and interfering with everyday activities such as sleep, work and study for two weeks 
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or more (NIH, 2016). Depression affects nearly 300 million people worldwide and is ranked 
by WHO as the single largest contributor to global disability (WHO, 2017). Depressive 
disorders are divided into two sub-categories: major depressive disorders; and dysthymia 
(WHO, 2017). 
Prevalence of depression among emerging adults living with HIV 
Depression is common among individuals living with HIV especially emerging adults (Abebe 
et al., 2019). Prevalence of depression among individuals living with HIV remains high as 
compared to their uninfected peers (Mellins & Malee, 2013). High rates of depression among 
emerging adults living with HIV could be attributed to HIV related psychosocial challenges 
that they may face such as stigma and burden of taking pills every day at the same time (Le 
Prevost et al., 2018; Mellins & Malee, 2013).  
Studies from High-income countries (HICs) have demonstrated that depression is common 
among emerging adults living with HIV. A cross sectional study of 335 emerging adults aged 
18 to 30 years from USA found a depression prevalence of 11.6% as measured by the Patient 
health questionnaire (PHQ-9) (Shacham et al., 2017). Similar results were also found in two 
studies that were conducted in USA and England, where the depression rates were 15.0% as 
measured by the Client Diagnostic Questionnaire (CDQ) among individuals aged 14 to 24 years 
and 16.0% as measured by the Hospital Anxiety and Depression Scale (HADS) among 
individuals aged 13 to 21 years  (Le Prevost et al., 2018; Martinez et al., 2009b). Two studies 
from USA among individuals aged 13 to 24 years and 12 to 24 years, found the prevalence of 
depression to be 24.0% and 32.1% respectively (Rudy et al., 2009; Salama et al., 2013). The 
highest rate of depression of 52.0% was found in a study that was conducted in USA among 
individuals aged 12 to 24 years using the Brief Symptom Inventory (BSI)  (Tanney et al., 2012).  
While the studies from HICs have shown that depression is prevalent among emerging adults 
living with HIV, the rates are not consistent as they range from 11.6% to 52.0%. This could be 
due to different tools being used to assess depression.  
Studies from low and middle income countries (LMICs) have also shown that depression is 
common among emerging adults living with HIV. The lowest prevalence of depression of 
12.1%, which was found in a study that was conducted in Tanzania among individuals aged 
12 to 24 years (Dow et al., 2016). The study screened for depression using the PHQ-9 which 
however, was not validated in their context (Dow et al., 2016). A study from South Africa that 
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examined depression in adults living with HIV aged 18 years and above, stratified by age found 
23.3% of emerging adults aged 18 to 29 years screened positive on the PHQ-9 (Cholera et al., 
2017). Although the study utilised a validated tool, the sample included in the study were 
adults who had unknown HIV status, and who identified as HIV positive at the study visit - i.e. 
newly diagnosed (Cholera et al., 2017).   
The highest prevalence of depression (35.5%) as assessed by the Beck Depression Inventory-
11  (BDI-11) was reported among individuals between the ages of 15 to 24 years in a study 
that was conducted in Tanzania although no information was provided on validation of the 
BDI-11 in that setting. (Abebe et al., 2019). While depression is prevalent in emerging adults 
residing in LMICs, the prevalence from the reviewed studies vary widely (12.1% to 35.5%).  
The wide range could be due to the use of different tools and age groups. Moreover, some 
studies from Africa were using tools that were not validated in their context.  
This review has shown that the rates for depression among emerging adults living with HIV 
residing in HICs (11.6% to 52.0%) differ from those residing in LMICs (12.1% to 35.5%). While 
emerging adults living with HIV both in HICs and LMICs, have to deal with HIV-related stressors 
such as managing disclosure, HIV-related stigma and the burden of taking HIV medication and 
its side effects, the highest prevalence of depression of 52.0% was reported in HICs (Abebe et 
al., 2019; Salama et al., 2013). There is a possibility that the prevalence of  depression in LMICs 
were underestimated since the majority of these studies used  tools that were developed in 
HICs and were not validated in their context. These tools could have not suited their cultures.  
Defining Anxiety disorders 
According to the DSM-5, anxiety disorders are mental conditions characterised by excessive 
fear and worry that are difficult to control and which can make life extremely difficult for 
individuals with these disorders (APA, 2013). It is estimated that 300 million individuals suffer 
from a range of anxiety disorders globally and they are ranked by WHO as the 6th largest 
contributor to global disability (WHO, 2017). The types of anxiety disorders include separation 
anxiety disorder, social anxiety disorder, panic disorder, and generalised anxiety disorders 
(GAD) (APA, 2013). This study focused on generalised anxiety disorder.   
Generalised anxiety disorder (GAD) is defined as a type of anxiety characterised by excessive 
worry and anxiety about several activities and events, such as family, work, health, money 
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etc. (APA, 2013). The symptoms of anxiety include worrying thoughts, fearful anticipation, 
muscle tension, disturbed sleep, sensitivity to noise, being easily fatigued, breathlessness, 
restlessness, irritability, dry mouth, and difficulty concentrating (Hoge, Ivkovic, & Fricchione, 
2012; Olagunju, Adeyemi, Erinfolami, & Ogundipe, 2012). Individuals with symptoms of GAD 
normally find it difficult to control their worry and this worry usually negatively affects how 
they function  (American Psychiatric Association, 2013).  
Prevalence of anxiety  
Compared to depression, there is limited evidence on the prevalence of anxiety among 
emerging adults living with HIV. A few studies conducted in different countries with varying 
age groups and using different instruments to measure anxiety have shown varying 
prevalence.  A study conducted in USA among emerging adults aged 18 to 30 years found the 
prevalence of anxiety to be 15.5% as assessed by the Generalised Anxiety Disorder 7 scale 
(GAD-7) (Shacham et al., 2017). Another study from USA found the rate of anxiety to be 37.8% 
using GAD-7 among those aged 18 to 34 years (Shacham et al., 2012). In England, 40.0% of 
individuals aged 13 to 21 years screened positive for anxiety on HADS (Le Prevost et al., 2018). 
A study from Nigeria (a LMIC) found 22.0% of HIV infected emerging adults aged 21 to 30 
years had an anxiety disorder using the Schedule for Clinical Assessment in Neuropsychiatry 
(SCAN) (Olagunju et al., 2012).  Although studies from both HICs and LMICs have shown 
varying rates of anxiety, they have all demonstrated that anxiety is highly prevalent among 
PLWH. High rates of anxiety among emerging adults in both HICs and LMICs could be 
attributed, in part, to the diagnosis of a chronic illness and the stigma associated with it.  
Varying rates could be explained by the use of different tools to screen for anxiety. For 
example a study conducted in United Sates of America (USA) among emerging adults aged 18 
to 30 years used the GAD-7 to screen for anxiety while in England the HADS was used to assess 
for anxiety among individuals aged 13 to 21 years (Le Prevost et al., 2018; Shacham et al., 
2017). In addition, prevalence estimates that are presented in this review included those aged 
below 18 years and above 29 years.  (Le Prevost et al., 2018; Shacham et al., 2012).  
Barriers to Antiretroviral Therapy adherence among HIV infected emerging adults  
This section aims to describe the barriers of antiretroviral therapy (ART) adherence that 
emerging adults living with HIV face regardless of their mental health conditions. The section 
begins by explaining what adherence means, why it is important and how emerging adults 
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adhere to ART compared to other age groups. Chapter 1 has provided the rate of non-
adherence among this age group.  
Adherence to antiretroviral therapy among emerging adults living with HIV 
Adherence can be defined as the extent to which patients take medication as prescribed 
(Paterson et al., 2000). In the HIV pandemic, optimal adherence to medication is required 
especially among emerging adults who are becoming sexually active (Asaolu et al., 2016; 
Naswa & Mafartia, 2010; Patel et al., 2007). Individuals who adhere to their medication are 
more likely to be virally suppressed thereby minimising the chances of transmitting the virus 
to their partners (Suleiman & Momo, 2016). Without good adherence, it is difficult to 
experience the benefits of the medication such as improved quality of life, and reduced 
mortality and morbidity rate (Gross & Hosek, 2016; Hornschuh et al., 2017; Vreeman et al., 
2017). Furthermore, as stated in the introduction chapter, poor adherence may contribute to 
drug resistance which  may lead to needing more complex treatment, which maybe expensive 
to purchase (Ehlers & Tshisuyi, 2015). 
Suboptimal ART adherence is higher in emerging adults compared to younger and older 
people (Palmer et al., 2018). A study conducted in USA found that emerging adults aged 17 
to 24 years had higher viral loads compared to older adults (Ryscavage et al., 2011).  Previous 
studies in SSA showed poorer HIV treatment outcomes including suboptimal adherence, 
missed clinic visits and high viral loads among emerging adults between the ages of 18 to 24 
years compared to younger adolescents (below 18 years) and older adults (Bygrave et al., 
2012; Maskew et al., 2016). 
Barriers to antiretroviral therapy adherence  
Studies that examined ART adherence reported several factors that can make emerging adults 
delay or skip taking their medications. Furthermore, there are several theories that can be 
used to explain non-adherence behaviour.  In this study, three theories including ecological 
model of health, Capability, Opportunity, Motivation and Behaviour (COM-B) model, and 
Necessity-Concerns Framework were used to explain barriers to ART adherence among 
emerging adults living with HIV.  
Ecological model for health promotion 
 While this study mainly focuses on the patient-related barriers to ART adherence, it is also 
important to have an understanding of other types of barriers of adherence including 
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interpersonal and structural that can make it difficult to take medications as prescribed. 
Barriers to ART adherence can be grouped in several ways. I used the ecological model for 
health promotion to explain the different levels of barriers to ART adherence among emerging 
adults living with HIV as shown below (Figure 2).  
The ecological model for health promotion was adopted from Bronfenbrenner’s ecological 
model in 1979 (Bronfenbrenner, 1977; McLeroy et al., 1988). Both models state that the 
individual’s behaviour is not only influenced by an individual’s attitude, beliefs, knowledge 
and skills but also by other environmental factors at different levels. According to the 
Brofenbrenner theory, behaviour can be influenced by microsystem, mesosystem, exosystem 
and macrosystem (Bronfenbrenner, 1977; McLeroy et al., 1988). The ecological model of 
health promotion, following the original Bronfenbrenner model, states that behaviour is 
determined by intrapersonal, interpersonal, institutional, , community and public policy 
factors (McLeroy et al., 1988). Intrapersonal factors are individual’s characteristics such as 
attitudes, behaviour, knowledge and self- concept, while the interpersonal factors involve 
informal and formal social network and social support systems including friends, work groups 
and family (McLeroy et al., 1988). Institutional factors are characteristics related to social 
institution and organizational rules and regulations for operation, while community factors 
are relationships among institutions, informal networks and organisations within defined 
boundaries. The public policy level involves state, local and national laws and policies 
(McLeroy et al., 1988). Adherence, just like any other behaviours, can also be influenced by 
the individual’s context at multiple levels (Fields et al., 2017). In relation to this review, 
barriers to ART adherence can be grouped into patient-related, interpersonal and structural 
barriers – a simplified version of McLeroy’s model (Davis et al., 2018).  
Patient-related barriers are factors that are related to the patient’s personal characteristics, 
behaviour, emotions and perceptions that can make it difficult for them to take their 
medications as prescribed (Castro et al., 2015). Some of the patient-related barriers to ART 
adherence include forgetting, fear of side effects, being away from home, depression and 
alcohol use (Fields et al., 2017; Hornschuh et al., 2017). The interpersonal barriers are factors 
that are related to interpersonal face to face relationships that are manifested in different 
contexts for example at home or at the hospital (Castro et al., 2015). Some of the 
interpersonal barriers to ART adherence may include poor relationships with the healthcare 
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providers, peer pressure and lack of social support (Castro et al., 2015; Davis et al., 2018). The 
structural barriers are institutional, cultural, economic and political factors that can affect 
adherence to medication, including poverty, lack of transport to healthcare providers, and 
long waiting time to receive treatment at clinics (Freed et al., 2013; Kagee et al., 2011). 
 
Figure 2: The ecological model for health promotion showing the different levels of barriers to 
ART adherence (adapted from Liu et al., (2018) and McLeroy et al., (1988)) 
Capability Opportunity Motivation -Behaviour change model (COM-B) 
The Capability, Opportunity, Motivation and Behavior (COM-B) model which forms part of the 
Behavior Change wheel framework, is a theory of behaviour that can contribute insights into 
adherence behaviour (Mcdonagh et al., 2018). The model was developed by Michie and 
according to the model, behavior is influenced by the components, namely capability, 
opportunity and motivation (see Fig 3) (Michie et al., 2011). Capability can be defined as a 
psychological (knowledge) or physical (skills) capacity to participate in the activity concerned; 
for example lack of knowledge and forgetting (Ayakaka et al., 2017; Mcdonagh et al., 2018).  
Opportunity can be defined as the social (societal influences) or physical (environmental 
resources) that makes a behaviour possible (Mcdonagh et al., 2018; Michie et al., 2011). 
Motivation  includes emotion, beliefs and intentions, or the brain processes that direct 
behaviour (Mcdonagh et al., 2018; Michie et al., 2011).  Using this theory helps to identify 
some of the barriers to ART adherence faced by emerging adults living with HIV. Furthermore, 
the theory can be used together with the Behaviour Change Wheel (BCW) to come up with 
Structural
Lac k  of fund for transportation
inadequate healthcare services
Alternative health therapy 
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fear of side effects
forgetting
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interventions that can improve adherence among emerging adults living with HIV (Mcdonagh 
et al., 2018) .  
 
Figure 3: COM-B adopted from (Michie et al., 2011)  
The Necessity-Concerns Framework 
The necessity-concerns theory was developed by Horne et al as an extension of common 
sense model of self-regulation (Chapman et al., 2015). The necessity theory suggests that 
patients’ adherence behaviour is influenced by their judgements of the personal need for 
treatment (necessity beliefs) and the concerns the patients have regarding the potential 
negative consequences of the treatment (concerns) (Chapman et al., 2015).  The theory states 
that, patients have pre-existing beliefs about their disease and medication, which may 
influence their evaluation, perception, adherence and health outcomes (Horne et al., 2013).  
This framework has shown to be useful in explaining adherence behaviour (Brandstetter et 
al., 2016). 
Common barriers to antiretroviral therapy adherence among emerging adults living with 
HIV 
Studies have shown that forgetting to take medication is one of the common barriers to ART 
adherence in both HICs and LMICs among emerging adults and adults above the age of 29 
years (Croome et al., 2017; MacDonell et al., 2013). Forgetting to take medication among 
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balancing work and school, college lifestyle and recreation (Fields et al., 2017). However, it is 
also possible that patients may report that they forgot when they deliberately decided not to 
take medication (MacDonell et al., 2013). 
Disclosure of HIV has also been reported as a major barrier to ART adherence among 
emerging adults in both LMICs and HICs (Fields et al., 2017; Mutwa et al., 2013; Nabukeera-
Barungi et al., 2015; Yang et al., 2018). Emerging adults are at stage where they engage in 
serious relationships and marriage where disclosure is needed (Sussman & Arnett, 2014). Fear 
of rejection by their partner complicates adherence as they may fail to take medications in 
front of them (Nabukeera-Barungi et al., 2015). Furthermore, emerging adults rarely disclose 
their HIV status to their peers due to fear of stigma and discrimination (Fields et al., 2017). 
When they are at college or boarding school where there is limited privacy, taking medication 
in front of peers who do not know their status is difficult. Hence they may delay or skip taking 
their medications (Maccarthy et al., 2018; Mutwa et al., 2013). For those who are working, 
fear of losing their jobs if people know their status can make it difficult for them to go to the 
hospital to get medications or to take their medication in front of others (Nabukeera-Barungi 
et al., 2015). 
Also, emerging adults living with HIV avoid taking pills as they constantly reminds them about 
their HIV status (Fields et al., 2017). For emerging adults who acquired HIV through vertical 
transmission, taking medication reminds them of how they grew up different from their 
uninfected peers who do not take medication (MacDonell et al., 2013). For newly diagnosed 
emerging adults, taking pills remind them of their new chronic illness (MacDonell et al., 2013).  
Factors related to treatment regimens among emerging adults living with HIV have been 
reported in low, middle and high-income countries. People who take ART medication usually 
complain of side effects especially with Tenolam E, a frequently used first line drug in 
Zimbabwe (Benton et al., 2013). Due to these side effects, such as stomach pain and nausea, 
many emerging adults delay or skip taking their medication (Fields et al., 2017; Galano et al., 
2016).  However, some patients tolerate the side effects of the medication for the sake of 
maintaining a healthy life (Rao et al., 2007). 
Another common barrier to ART adherence among individuals living with HIV is being away 
from home (Croome et al., 2017). Emerging adults are at a stage where they want to explore 
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new things and are less monitored by their parents or caregivers (Arnett, 2014). During this 
period hanging out with friends, parties and sleepovers are common (Hornschuh et al., 2017). 
When they are away from home with their peers, HIV infected emerging adults skip their 
medication due to fear of unintended disclosure, embarrassment and HIV related stigma and 
discrimination (Hornschuh et al., 2017). 
In LMICs, poverty is one of the major barrier among emerging adults, especially orphans 
(Nabukeera-Barungi et al., 2015). In Sub Saharan Africa (SSA), there is a high unemployment 
rate and this directly affects emerging adults who are at a stage of looking for employment 
(Banks, 2016; Maccarthy et al., 2018). Unemployment is associated with poverty. Poverty 
makes it difficult for them to buy food which they are supposed to eat before swallowing their 
medication to avoid side effects related to taking medication on an empty stomach 
(Maccarthy et al., 2018; Yang et al., 2018). Also, emerging adults living in poverty usually find 
it difficult to get money for the transport to go to the hospital which may lead to defaulting 
on their medications (Nabukeera-Barungi et al., 2015). 
 Prevalence of barriers to ART adherence among emerging adults living with HIV  
Although there are studies that focused on barriers to ART adherence among emerging adults, 
few indicated the proportion of emerging adults who experienced the barriers to ART 
adherence. One such study was a cross sectional study conducted in USA among individuals 
aged 12 to 24 years (Rudy et al., 2010). They found that 47.2% experienced at least one barrier 
to ART adherence  (Rudy et al., 2010). A similar cross sectional study conducted at an HIV 
clinic in Harare, Zimbabwe, among adults reported that 48.0% of adults living with HIV aged 
18 years and above experienced at least one patient-related barrier to ART (Croome et al., 
2018). While these studies were conducted in different settings, their results are similar. 
However, these studies did not compare the prevalence of barriers to ART adherence 
between those with CMDs and those without CMDs.  
Common mental disorders and barriers to antiretroviral therapy among emerging 
adults living with HIV 
This section aims to describe barriers to ART adherence among emerging adults living with 
HIV and CMDs in comparison to those without . There are limited studies that compared the 
prevalence, number, severity and common barriers to ART adherence between emerging 
adults with CMDs and those without CMDs. Therefore, this section will mainly describe the 
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barriers to ART adherence among emerging adults with CMDs without comparing to those 
without CMDs. 
Studies suggest that depression is associated with poor adherence (Morrison et al., 2011). 
This could be because the depressive symptoms, such as loss of interest, feeling of 
worthlessness, poor concentration and suicidal thoughts, can impair certain functions, such 
as memory, information processing, which in turn negatively affect self-management 
activities that are necessary for HIV treatment (Gonzalez, Abigail W. Batchelder, et al., 2011). 
Due to these symptoms of depression, HIV infected emerging adults with CMDs are more 
likely to experience certain barriers to ART adherence more frequently than those without 
CMDs.  For instance, HIV infected emerging adults with CMDs are at higher risk of alcohol use 
compared to those without CMDs as they may use alcohol as a treatment to reduce symptoms 
of CMDs (Mckenzie et al., 2011). As such, HIV emerging adults with CMDs are more likely to 
report alcohol use as a barrier to adherence compared to HIV emerging adults without CMDs. 
Both depression and alcohol can affect decisions about taking ART on time (Fields et al., 2017). 
Although forgetting has been reported as a common barrier to ART adherence among HIV 
emerging adults, regardless of mental health condition, this could be more common among 
those with CMDs. A study in Zimbabwe found forgetting to be a common barrier among HIV 
infected adults with depression (Kidia et al., 2015). This is because, as explained in chapter 1, 
depression can impair memory and concentration, which may result in one forgetting to take 
his or her medications. 
Furthermore, emerging adults with CMDs are likely to report barriers due to their mental 
conditions. A study conducted in Zimbabwe among adults living with HIV aged 18 years and 
above has shown that as the scores of depression on PHQ-9 increase (i.e. increase in 
depressive symptoms), the total score of barriers to ART experienced by participants also 
increased (Croome et al., 2018). However, in that study the results were not stratified 
according to age, making it difficult to generalise these results among emerging adults.   
Also there is a possibility that emerging adults with CMDs report a higher number of barriers 
to ART adherence compared to those without CMDs. A study that was conducted in USA 
among adolescents and emerging adults aged 14 to 24 years (MacDonell et al., 2013) found 
that a high total number of barriers to ART adherence was associated with high psychological 
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stress (MacDonell et al., 2013). Having multiple barriers to ART adherence has been found to 
be associated with worse adherence (Rudy et al., 2009). 
Literature Gap 
In SSA, where the HIV prevalence rate is still high in emerging adults, depression and anxiety 
among this population remain under diagnosed. Research on mental health, for example in 
Zimbabwe, mainly focused on the adult population, a few on adolescents, but emerging 
adults were generally underrepresented (Abas et al., 2017; Chibanda, Benjamin, Weiss, & 
Abas, 2014; Chibanda, Cowan, et al., 2016b; Kidia et al., 2015; Willis et al., 2018). Also at the 
clinic where emerging adults receive treatment for HIV in Harare, the primary concern for 
their appointments is to receive treatment for HIV and to receive ART drugs rather than 
identify their risk of mental disorders (Martinez et al., 2009a). Hence, HIV clinic services are 
not necessarily aware of the prevalence of CMDs among emerging adults living with HIV. 
Failure to screen and treat CMDs may contribute to non-adherence to HIV medication among 
this population (Martinez et al., 2009b). 
While there are studies on barriers to ART adherence, to my knowledge there are no studies 
that examined barriers to ART adherence among HIV infected emerging adults with CMDs in 
SSA particularly in Zimbabwe.  Finding from such studies may guide future studies, adherence 
counselling and development of interventions that treat CMDs and reduce barriers to ART 
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CHAPTER 3: METHODOLOGY 
This chapter focuses on the research methodology used to conduct this study. The chapter 
outlines the research design, study site, study population and sampling procedure. It further 
explains the recruitment, data collection procedure, tools, data analysis procedures, ethical 
considerations and the conflict of interest.  
  Objectives 
1. To determine the prevalence of probable common mental disorders (CMDs) (i.e. 
depression and/or anxiety) among emerging adults living with HIV accessing 
treatment at the Parirenyatwa Centre of Excellence 
2.  To describe the prevalence, number, type and severity of barriers to ART adherence, 
measured using the 22-item Barriers to Adherence scale (BARTA scale) in emerging 
adults living with HIV with probable CMDs and to compare this with those without 
probable CMDs.  
Hypothesis 
1. Emerging adults living with HIV with probable common mental disorders have a 
greater number of barriers to ART adherence than those without probable common 
mental disorders 
2. Barriers to ART adherence are more severe (high total BARTA score)  among emerging 
adults with probable common mental disorders than those without common mental 
disorders. 
Study Design 
The study adopted a cross-sectional survey study design. Cross-sectional studies are carried 
out in order to find out the prevalence of a given population characteristic and to compare 
different populations at one point in time (Pandis, 2014). This design was suitable for the 
study because the primary aim of the study was to describe prevalence of CMDs and of 
barriers to ART adherence in emerging adults living with HIV, and to test the hypothesis that 
those with CMDs compared to those without CMDs would have more barriers to ART 
adherence. The independent variables and the outcome were collected at the same time 
point for each participant.  
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Study Site  
The study was carried out at Parirenyatwa Centre of Excellence – the HIV clinic. The 
Parirenyatwa Group of Hospitals is the second largest referral hospital located in the capital 
city of Zimbabwe, Harare.  The clinic is affiliated with the University of Zimbabwe College of 
Health Sciences. Parirenyatwa Centre of Excellence provides services that include HIV 
counselling and testing, initiating both adults and children on ART and offering adherence 
counselling. At the time of data collection for the study, there were approximately 4923 
patients registered at the clinic and on ART. Nearly 2979 of these visit the clinic routinely for 
their repeat medications, physical check-up, viral load and CD4 count tests. A total of 886 
emerging adults aged 18 to 29 years were registered at the HIV Clinic, while only 521 of these 
were coming for their regular follow up visits. Doctors, nurses and primary care counsellors 
provide the services. Although all the doctors and nurses have undergone training for 
screening of mental disorders, the clinic has not implemented routine mental health 
screening. Patients suspected of having severe mental disorders are referred to a psychiatrist 
who visits the clinic by appointment, or are referred to Parirenyatwa Hospital-Annex, a mental 
health referral hospital in Harare. It is situated 200 metres outside the main Parirenyatwa 
Hospital. 
Participants 
The study population were emerging adults aged 18 to 29 years.  
Inclusion criteria 
Participants were 
• Between the ages of 18 and 29 years  
• Registered at Parirenyatwa Centre of Excellence  
• Had initiated ART at least 1 month prior to the interview  
Exclusion Criteria 
• Patients below the age of 18 and above 29 years 
• Emerging adults who were considered by the doctors or nurses to be too physically or 
severely mental ill to be able to answer the questionnaire 
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Sample size calculation  
A sample size is the number of participants that should be included in the study in order to 
answer a research question (Noordzij et al., 2011). For a sample size for a cross-sectional study 
to be calculated, the level of confidence, an estimated prevalence rate and degree of precision 
are required (Kasiulevičius et al., 2006). In this study, the level of confidence was 95.0% and 
the degree of precision ±5.0%. The estimated prevalence rate of depression of 11.6% was 
based on the previous research among emerging adults aged 18 to 30 years living with HIV 
(Shacham et al., 2017). The previous study used the age group and tool to measure depression 
that is similar to this current study.  















  = 158 
Where n= sample size 
 z= statistics corresponding to 95% confidence (this will be set at 1.96) 
 p= prevalence (this was obtained from the previous study) 
 d= the degree of precision (this will be set at 0.05 or 5.0%) 
To compensate for participants who would have refused to participate or stop half way during 
the assessment, the sample size was adjusted upwards by 10.0%. Thus, the minimum sample 
aimed to recruit was 173. However, I planned to increase the sample size in order to provide 
for a more robust sample if time and funding permitted.  
Recruitment  
The researcher or research assistant (RA) first informed all potential participants about the 
study through announcing the study in the hall where patients normally wait to collect pills. 
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They explained the purpose of the study, the sampling process that participation is voluntary, 
and participants would not lose any of their usual care if they declined to participate.  Selected 
potential participants were invited to a private and quiet room, one at a time, where the 
researcher or RA fully explained the purpose of the study, procedure and consenting process. 
After explaining the purpose of the study, the invited potential participants were screened 
for eligibility. All patients who were approached were recorded in the screening log (see 
appendix A).  Eligible participants were interviewed one at a time in a private and quiet room.  
Sampling procedures  
Simple random sampling was used to select participants. The researcher/RA was provided 
with a list of emerging adults that were booked for a visit on that particular day. The clinic 
operates from Monday to Friday; hence, data were collected during these week days. The aim 
was to recruit 12 participants per day. All patients on the list were assigned with a unique 
number. The numbers were then placed in a hat or container and the blindfolded RA picked 
any 12 numbers from the hat or container. Individuals with numbers selected were invited to 
a private room as explained above. In cases where some of the participants from the 12 
selected were not eligible, they were not replaced by another participant, rather they were 
noted as non-response.  If there were 12 emerging adults or less booked on a particular day, 
they were all invited to take part in the study. This method was appropriate for this study as 
it ensures that all eligible patients have an equal chance of being recruited (Singh & Masuku, 
2014). Furthermore, it minimises the chances of selection bias (Singh & Masuku, 2014). 
 








Figure 4: A flow chart illustrating the recruitment process  
Data Collection 
Eligible participants who agreed to take part in the study were asked to sign the consent form 
before they started answering the questionnaire. The questionnaire was administered in the 
participant’s language of choice (either English or Shona) by the researcher or RA. Before 
administering the questionnaire, the researcher or RA explained to the participant how to 
answer the questions. Participants were encouraged to ask the researcher or RA if they did 
not understand any question. All data for a participant was collected on the same day. 
Included if 
• Aged between 18 and 29 years 
• Registered at Parirenyatwa centre 
of excellence 
Excluded if 
• Below 18 years 
• Above 29 years 
• Not registered at Parirenyatwa 
centre of excellence 
• Too ill  
Consenting 
Sampling procedure 
The researcher/ research assistants selected participants through simple random sampling 
Sensitization 
The researcher/ research assistant announced the study in the hall 
Recruitment 
Recruitment process was done using the inclusion and exclusion criteria  
Referral 
Participants who screened positive on any 
mental disorder were referred to the 
doctors at the clinic and annex hospital 
Reimbursements 
All participants who took part were 
provided with refreshments to 
compensate for their time 
Completing questionnaire 
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Participants were recruited from Monday to Friday every week from 01 March 2019 to 31 July 
2019. 
Measures and instruments 
In order to collect data, five instruments were used: Patient Health Questionnaire (PHQ-9), 
Generalized Anxiety Disorders Scale (GAD-7), Alcohol Use Disorder Identification Test 
Consumption (AUDIT-C), Drug Use Disorders Identification Test (DUDIT) and Barriers to ART 
Adherence (BARTA).  Information on demographic and HIV-related characteristics were also 
collected. Detailed information about the instruments is provided below. All these 
instruments are self-report. 
Demographic and HIV- related variables (Appendix B) 
The first part of the questionnaire consisted of demographic and HIV-related questions. Some 
of the questions included date of birth, age, sex, orphan hood status, highest level of 
education, marital status, and current employment status. 
HIV-related data included the following questions: Why are you attending the clinic today?; 
How do you think you got infected?; Are you on ART medication?; When did you initiate ART?; 
and did you disclose your status to anyone outside of the clinic, and if yes to who?  
Barriers to ART Adherence (BARTA) scale (Appendix C) 
Barriers to ART adherence were measured using the tool called Barriers to ART Adherence 
scale (BARTA). This tool was developed in Zimbabwe in order to measure barriers to ART 
adherence for adult populations (18 years and above) (Croome et al., 2018). This tool has 
been recently validated in Zimbabwe and translated into Shona (Croome et al., 2018). The 
tool consists of 22 items and for each item patients are asked if they skipped or delayed taking 
their HIV medicines in the past month due to a specific reason. For example:  
a. I did not take all of my HIV medicines on time because of religious or spiritual beliefs 
b. I did not take all of my HIV medicines on time because I did not believe they were 
important for my current health  (see appendix C for the other 20 items)Each item is scored 
on a five-point scale ranging from 0-4 (never-0, rarely-1, some of the time-2, most of the time-
3 and always-4). The range for the total score is zero to 88.   
In this study, the tool was used to measure different aspects of barriers to ART adherence: 
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a) Severity of barriers to ART adherence- this was measured as the total score. The total score 
is obtained by adding up the scores for the 22 items. The greater the score the more barriers 
a participant experiences and/or the more frequently a participant experiences barriers. The 
total score was used to measure severity.  
b) Prevalence of barriers to ART adherence- this was measured by dichotomising the total 
BARTA score: those who reported no barriers (total score 0) and those who reported at least 
one barrier (total score>=1).  
c) Total number of barriers- Each item score was dichotomised as 0 (no barrier) 1 (experience 
the barrier at least rarely). The binary scores were then added up to create a variable 
reflecting the reported number of barriers regardless of severity.  
Patient Health Questionnaire-9 (PHQ-9) (Appendix D) 
PHQ-9 is an instrument for screening depression based on Diagnostic and Statistical Manual 
of mental disorders 4th edition (DSM-IV) (Kroenke et al., 2001). The instrument can be self-
administered or be interviewer administered in five minutes and can be easily scored 
(Kroenke et al., 2001).   
The instrument asks the patients how often they have been bothered by each of the PHQ-9 
symptoms over the last two weeks (Bhatta et al., 2018). It consists of nine items and each 
item is scored from 0 (not at all) to 3 (nearly every day) (Kroenke et al., 2001). The scores 
range from 0 which indicates that there are no symptoms of depression to 27 which indicates 
all symptoms are occurring everyday (Abas et al., 2017). A score of 5 – 9 is defined as mild 
depression symptoms while 10 – 14 represent moderate depression symptoms, 15 – 19 
represent moderately severe depression symptoms and 20 and above is defined as severe 
depression (Kroenke et al., 2001). 
This tool has been validated in Zimbabwe in those aged 18 years and above with an optimal 
cut off ≥11, sensitivity of 85.0% and specificity of 69.0% against a Structured Clinical Interview 
SCID diagnosis of depression (Cronbach α=0.86) (Chibanda, Verhey, et al., 2016). For binary 
outcome, a score of 11 or above was considered to be a positive screen for probable 
depression, while a score of below 11 was regarded as absence of depressive symptoms 
(Chibanda, Verhey, et al., 2016).  
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PHQ-9 has been translated into the local language Shona and it has been used in various 
studies in Zimbabwe to estimate the prevalence of probable depression among the adult 
population (Abas et al., 2017; Chibanda, Verhey, et al., 2016).  
Generalized Anxiety Disorder scale (GAD-7) (Appendix E) 
GAD-7 is a tool used to assess the existence of an anxiety disorder as well as their severity 
(Spitzer et al., 2006). The tool consists of 7 items that are rated on a 4 point scale from 0 (not 
at all) to 3 (nearly every day) and the score ranges from 0 to 21 (Spitzer et al., 2006). The tool 
takes about 5 minutes to complete. This tool has been translated into Shona and validated in 
Zimbabwe. The optimum cut off is ≥10 with a sensitivity of 89.0% and specificity of 73.0% 
(Chibanda, Verhey, et al., 2016). A score of 10 and above on GAD-7 is regarded as meeting 
criteria for probable anxiety. 
Alcohol Use Disorder Identification Test- Consumption (AUDIT-C) (Appendix F) 
The AUDIT-C was used to measure the frequency and quantity of alcohol consumption. This 
tool was developed from the Alcohol Use Disorder Identification Test (AUDIT) (Babor et al., 
2001; Frank et al., 2008). It consist of a 3 item alcohol screen which are the first three 
questions on the AUDIT questionnaire (Bradley et al., 2007). AUDIT-C has not been validated 
in SSA but other countries in this region have validated the full AUDIT including in Zambia 
(Chishinga et al., 2011). The tool has been translated into Shona in a previous Zimbabwean 
study and has been used to screen for alcohol misuse among PLWH in some studies conducted 
in SSA (Abas et al., 2017; Asiimwe et al., 2015; Kruse et al., 2015).  Also the tool has been used 
to screen for alcohol misuse among emerging adults residing in South Africa (Gevers et al., 
2013; Louw et al., 2012). AUDIT-C helps to identify individuals who have active alcohol 
dependence and alcohol abuse or hazardous drinkers (Dawson et al., 2005).  The total score 
ranges from 0 to 12 and the response option of each item is scored on a 0 to 4 point scale, 
with higher scores indicating more alcohol use (Frank et al., 2008). In USA, cut off scores of 
≥3 (with a sensitivity of 0.73 and specificity of 0.93) and ≥4 (with sensitivity of 0.86 and 
specificity of 0.89) in women and men respectively are regarded as an indicator of hazardous 
drinking (Bradley et al., 2007). A score of 4 and above for men and a score of 3 and above for 
women will be regarded as unhealthy drinking (Asiimwe et al., 2015). In this study, these cut 
off points were used to indicate probable alcohol use disorders. 
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Drug Use Disorders Identification Test (DUDIT) (Appendix G) 
The DUDIT was used to measure the frequency and quantity of drug use. DUDIT is a tool that 
is used to screen for substance abuse other than alcohol use disorders (Kader et al., 2015). It 
consists of 11 items, with the first 9 being scored on a five point scale ranging from 0-4 and 
the last two are scored on a 3 point scale with values 0, 2 and 4 (Hildebrand et al., 2015). In 
total the scores range from 0-44 (Vythilingum et al., 2012). Scores of ≥6 and ≥2 indicate 
symptoms of substance abuse in men and women, respectively (Kader et al., 2015; 
Vythilingum et al., 2012). In this study, these cut off points were used to indicate probable 
substance use disorders. This tool has not been validated in Zimbabwe, but it has been used 
in previous studies in Zimbabwe and other SSA countries to assess symptoms of substance 
use among PLHIV (Kader et al., 2015; Madhombiro et al., 2017).  
The overall questionnaire was administered in the following order; 
1. Demographic and HIV-related variables  
2. Barriers to ART Adherence 
a. Barriers to ART adherence scale (BARTA) 
3. Mental health 
a. Patient Health Questionnaire-9 (PHQ9) 
b. Generalized anxiety disorder-7 (GAD-7) 
c. Alcohol Use Disorder Identification Test Consumption (AUDIT) 
d. Drug Use Disorder Identification Test (DUDIT) 
Data Analysis 
Collected data were entered into Redcap, cleaned, and exported into STATA version 14, which 
was used to analyse the data. I used univariate, bivariate and multivariate analyses as 
described below. 
Univariate analysis 
Univariate statistics are statistics that analyse a single phenomenon (Bertani et al., 2018) and 
may include frequencies and measures of central tendency. In this current study, the 
following frequencies are reported: 
1. socio-demographic variables including age, gender and employment status; 
2. prevalence of CMDs (i.e. depression and/or anxiety);  
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3. prevalence of substance use disorders (alcohol use disorder and/or drug use disorder);  
4. proportion of participants with barriers to ART adherence 
5. the overall median of total BARTA score (severity of barriers to ART adherence) for  
the whole sample 
6. the overall median number of barriers to ART adherence for the whole sample 
Normality tests using the Shapiro-Wilk Shapiro Francia and skewness/ kurtosis tests, were 
conducted in order to determine if the scores for BARTA were normally distributed. All 
tests found that the scores were not normally distributed. Thus, non-parametric tests 
were used when conducting bivariate analyses involving the BARTA scores. 
Bivariate analysis 
Bivariate statistics are statistics that are used to analyse the relationship between two 
variables (i.e. the independent and dependent variables) (Muijs, 2004). Chi-square analyses 
were used to compare the prevalence of barriers (no barrier vs at least one) between 
participants with and without a CMD. As a way of reducing type 1 error, only descriptive are 
reported in the results sections for prevalence of each type of barrier by CMD. Chi-square 
analyses were also used to compare demographic and HIV related variables between those 
with and without CMDs. Non-parametric Wilcoxon rank-sum tests (also known as the Mann-
Whitney U test) were used  to (i) compare the number of barriers to ART between participants 
with and without a CMD; and (ii) compare the severity of barriers to ART (total BARTA score) 
between participants with and without a CMD, using overall scores on the BARTA.  
Negative binomial regression 
Mann-Whitney U tests (for binary variables) and Kruskal Wallis tests (for variables with more 
than 2 categories) were conducted to assess the relationship between demographic variables, 
HIV-related variables, SUDs and total BARTA scores. Variables that were significantly 
associated with BARTA scores were then entered into a negative binomial regression model, 
to assess the relationship between CMDs and severity of barriers to ART adherence, this time 
controlling for possible demographic confounding factors. A negative binomial regression was 
used because the data did not meet the assumptions of a linear regression. 
Ethical Considerations 
University of Cape Town Human Research Ethics Committee (652/2018), the Joint 
Parirenyatwa hospital and College of Health Sciences Research Ethics Committee (JREC 
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297/18) and Medical Research Council of Zimbabwe (B/1623) approved the study before it 
commenced. 
Consenting  
Before the interview began, the researcher or RA provided detailed information to the 
participant about the study such as benefits and possible risks of the study.  The consent 
forms were in English and Shona. Participants were allowed to read and sign a consent form 
in the language of their choice. All participants who agreed to participate signed a  consent 
form before starting the interview.  
Confidentiality 
All information collected in this study remains private and confidential. No third party had 
access to the information. Confidentiality was only breached if a participant screened positive 
on any CMDs or was at risk of suicide (i.e. if they score ‘more than zero’ on the suicidal item 
on PHQ-9 questionnaire). The Parirenyatwa Centre of Excellence has a multi-disciplinary care 
team with a psychiatrist, psychologist and physician. Participants who screened positive to 
any of the CMDs or who were at risk of suicide were referred to this multi-disciplinary care 
team for further assessment and consideration for treatment. In order to ensure anonymity, 
the researcher did not use the participants’ real names in the study, but assigned ID numbers. 
The real names of the participants only appeared on the consent and compensation form 
where they signed to indicate that they have received refreshments. The compensation form 
included the following information: name of the participant, participant ID, date of 
recruitment, refreshments received, participant phone number, address and signature. 
Consent and compensation forms were kept separate from the other questionnaires so that 
the information provided remained confidential.  
All data collected in this study were kept in a password-protected database and no 
unauthorised individual had access to the data. All paperwork was kept in a locked cupboard 
and a locked office. Only authorised people had access to the paperwork.    
Risk or Benefits 
There were no direct benefits for participants that were enrolled in this study. Minimal risk of 
participants having an emotional reaction to the questions was anticipated. In such cases, the 
researcher (a research psychologist) or RA determined if further referral was required as 
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described above. Both the researcher and RA had the necessary skills to identify emotional 
reactions. 
Cost, compensation and reimbursements 
There were no costs for participants since the study was conducted at the clinic. However, 
participants received refreshments during the interview.  
Conflict of interest 
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CHAPTER 4: RESULTS 
This chapter focuses on analysing and presenting findings of the study. The findings are 
presented according to the objectives of the study. The chapter will however start by 
presenting on the total number of participants who were included and excluded in the study 
as well as the findings on the socio-demographic characteristics. 
Sample characteristics   
Between 5 March and 17 July 2019, 268 emerging adults living with HIV at Parirenyatwa 
centre of excellence were invited to take part in this study. Of these, 223 (83.2%) participants 
were recruited, which exceeded the minimum sample required and provided a robust sample.  
In total 45 (16.8%) participants were excluded from the study; of these 11 (4.1%) were 
excluded as they did not meet the inclusion criteria (i.e. did not fit age criteria or were too ill 
to participate), and another 34 participants (12.7%) refused to participate. This is illustrated 
in Fig 4. Reasons given by participants who refused to participate include being in a rush, not 
interested in taking part in studies, and wanting to go home and rest.   
 
Figure 5: Flow chart showing the recruited and excluded participants 
 
Excluded participants, n=11 (4.1%) 
Participants not meeting the criteria 
1. Above 29 years, n= 8 (3.0%) 
2. Below 18 years, n= 1(0.4%) 
3. Too ill, n=2 (0.75%) 
 
 





Participants not willing to 
participate, 
1. Did not sign consent= 14 
(31.1%) 
2. Other reasons stated, n= 20 
(44.0%) 
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Of the 223 participants included in the analysis, 134 (60.1%) were females and 89 (39.9%) 
were males, as shown in the Table 2 below.  
Participants recruited were between the ages of 18 to 29 years, with a mean age of 23, and 
the majority were between the ages 18 to 24 years (73.5%).  
Only 55 (24.7%) of the participants had both parents alive while the majority were orphans, 
with 72 (32.3%) having lost both parents, 52 (23.3%) having lost a father only and 44 (19.7%) 
having lost a mother only. The majority of the participants completed secondary school (175, 
78.5%) while only 1 (0.5%) participant had not attended school (see Table 2 below). The 
largest proportion were unemployed (n=88, 39.5%), while 70 (31.4%) were employed either 
part time, full time or self-employed, and 65 (29.2%) participants were still at secondary 
school or at a tertiary institution. The majority of the participants were single (n=153, 68.6%) 
whereas 29 (13.0%) participants were married, 17 (7.6%) were cohabiting, 22 (9.9%) were 
divorced or separated and 2 (0.9%) were widowed.   
Table 2 shows the socio-demographic information of the participants by CMD. There was a 
significant difference for gender, employment status and marital status between participants 
with CMDs and those without. Participants who were unemployed (16.1%; p=0.030) were 
significantly more likely to have CMDs than those who were self-employed (5.8%), employed 
part-time (2.2%), employed full time (3.4%) and students (5.4%). Similarly, participants who 
were single (17.5%) were significantly more likely (p=0.003) to have CMDs than those who 
were cohabiting (3.6%), married (5.8%) and divorced/separated/widowed (6.3%). Females 
(23.3%) were significantly more likely (p=0.029) to report a CMD than males (9.9%) . 
There was no significant difference for age (p=0.154), orphanhood status (p=0.795) and level 
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Table 2: Socio-demographic characteristics of emerging adults living with HIV, by CMD status 
(n=223) 
Variable Category  CMDs 
 
  
Total No Yes p-value   
N % N % N %  
Gender 
 
Female 134 60.1 82 36.8 52 23.3 0.029 
Male 89 39.9 67 30.0 22 9.9  
Age bracket 
 
18 to 24 years 164 73.5 114 51.1 50 22.4 0.154 
25 to 29 years 59 26.5 35 15.7 24 10.8  
Orphanhood 
status 




Lost a mother 44 19.7 32 14.4 12 5.4  
Lost a father 52 23.3 34 15.3 18 8.1  
Lost both parents 72 32.3 46 20.6 26 11.7  
Highest level of 
education 
Primary school or less 13 5.8 5 2.2 8 3.4 0.060 
 Secondary school 175 78.5 118 52.9 57 25.7  







Student 65 29.2 53 23.8 12 5.4 0.030 
Employed full time 27 12.1 19 8.5 8 3.4  
Employed part time 14 6.3 9 4.0 5 2.2  
Self employed 29 13.0 16 7.2 13 5.8  





Single 153 68.6 114 51.1 39 17.5 0.003 
Cohabiting 17 7.6 9 4.0 8 3.6  
Married 29 13.0 16 7.2 13 5.8  
Divorced/ 
separated/widowed 
24 10.8 9 4.5 14 6.3  
 
HIV-related characteristics are reported in Table 3. All participants were taking ART for more 
than a month when they were recruited in the study. The majority of participants reported 
that they were HIV positive through vertical transmission (n=144, 64.6%), with 27.3% infected 
behaviourally, and 16 (7.1%) did not know how they got infected. The majority of the 
participants had disclosed their status 140 (62.8%). Participants who vertically acquired HIV 
(17.0%) were significantly more likely (0.009) to have a CMD than those who acquired HIV 
through behavioural transmission (11.7%). Participants who disclosed their status (22.9%) 
were more likely to report a CMD than those who did not (10.3%) and the difference was not 
significant (0.181). 
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Table 3: HIV related characteristics (n=223) 
 
 
In this study, alcohol and drug use were not reported as probable CMDs, but as probable 
SUDs. Probable SUDs are reported in Table 4. Altogether, 38 (17.0%) participants screened 
positive on the AUDIT-C and were at risk of alcohol use disorder, while 19 (8.5%) participants 
screened positive on the DUDIT. Thus, 43 (19.3%) participants had probable substance use 
disorders.  






Prevalence of common mental disorders  
The prevalence of probable CMDs (i.e. probable depression and/or probable anxiety) was 
33.2% (n=74). Specifically, 71 participants (31.8%) had probable depression only and 36 
(16.1%) had probable anxiety only. A higher proportion of females reported a CMD (n=52, 
38.8%) compared to their male counterparts (n=22, 24.7%), as shown in Table 5.   
 
 
Variable Category Total CMDs P-Value 
  No Yes 
N % N % N % 
On ART medications for 
more than 1 month 
Yes  223 100.0      
Mode of HIV transmission Behaviourally & other means 61 27.4 35 15.7 26 11.7 0.009 
Vertical 144 64.6 106 47.5 38 17.0 
Unknown or declined  18 8.0 8 3.4 10 4.0 
Disclosed status to anyone Yes 140 62.8 89 40.0 51 22.9 0.181 





Probable Alcohol Use   38 17.0% 
Probable Drug Use  8.5% 
19 
Probable SUDs ( alcohol use and/or 
substance use) 
43 19.3% 
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Barriers to antiretroviral therapy adherence 
Out of a total sample of 223, the majority 170 (76.2%) experienced at least one barrier to 
adherence.  Figure 5 presents the box plot of the total BARTA score for the 223 participants, 
with the median of 3 and interquartile (IQR) of 1-7. The minimum score was ‘0’ while the 
maximum score was ‘15’ excluding the outliers. There were 7 outliers and the highest score 
was 49.  The participant with the highest score (49) was included in all analyses.  
 
Figure 5: Box plot showing the interquartile range for the total BARTA scores (severity of 
















Variable Category Frequency Percentage (%) 
Probable Depression   
Total (yes) (n=223)  71 31.8 
Gender Males (n=89) 21  23.6 
Females (n=134) 50  37.3 
Probable Anxiety 
Total (yes)   36 16.1 
Gender Male (n=89) 7 7.9 
Female (n=134) 29 21.6 
Probable CMDs (depression and/or anxiety) 
Total  (yes) (n=223)  74 33.2 
Gender Male (n=89) 22 24.7 
Female (n=134) 52 38.8 
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The box plot below (Figure 6) shows the average number of barriers to ART adherence 
reported among the 223 participants. Participants reported on average 3 barriers to ART 
adherence, with an IQR of 1-5. The minimum score was ‘0’ while the maximum score was ‘12’. 
There were 4 outliers and 17 was the highest score. 
 
Figure 6: Box plot showing the interquartile range for the total number of barriers to ART 
adherence for the whole sample 
 
Table 6 below shows the descriptive statistics for barriers to ART adherence for the full sample 
and by the existence of CMDs. The most common barrier that was reported by the full sample 
was ‘forgetting’ (42.0%). This was followed by ‘not having the medications with them’ 
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Table 6: Cross tabulation of Barriers to ART adherence and Common mental disorders 
Barrier  
 
Full sample  
(n, %) (n=223) 
Participants with 
CMDs (n, %) (n=74) 
 Participants 
without CMDs  
(n, %) (n=149) 
Forgot 94 (42.2) 50 (67.6) 44  (29.5) 
I did not have them with me 60 (26.9) 28 (37.8) 32 (21.5) 
Did not have a reminder 58 (26.0) 29 (39.2) 29 (19.5) 
I did not want people to know my status 57 (25.6) 27 (36.5) 30 (20.2) 
Busy  54 (24.2) 28 (37.8) 26 (17.5) 
I was thinking too much or felt stressed 49 (22.0) 36 (48.7) 13 (8.7) 
A change in my daily routine 46 (20.6) 28 (37.8) 18 (12.1) 
Had to take them in front of others 45 (20.1) 30 (40.5) 15 (10.1) 
I was asleep when I was supposed to take 
them 
44 (19.7) 25 (33.8) 19 (12.7) 
I did not believe they were important for 
my current health 
32 (14.4) 21 (28.4) 11 (7.4) 
I did not fully understand how or when to 
take them 
26 (11.7) 12 (16.2) 14 (9.4) 
Side effects 26 (11.7) 14 (18.9) 12 (8.1) 
Tired of taking my pills 25 (11.2) 7 (9.5) 18 (12.1) 
Felt they were harmful 22 (9.9) 15 (20.3) 7 (4.7) 
Drinking alcohol 22 (9.9) 12 (16.2) 10 (6.7) 
Feeling well 21 (9.4) 9 (12.2) 12 (8.1) 
Worried about the long term effects of my 
medicines 
16 (7.2) 9 (12.2) 7 (4.7) 
Felt sick or ill 16 (7.2) 10 (13.5) 6 (4.0) 
Did not fully understand how they work 13 (5.8) 6 (8.1) 7 (4.7) 
Worried about them interacting with other 
medication I have to take 
8 (3.6) 6 (8.1) 2 (1.3) 
Did not have enough food to eat  11 (4.9) 8 (10.8) 3 (2.0) 
Religious or spiritual beliefs 7 (3.1) 4 (5.4) 3 (2.1) 
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Barriers to ART adherence and common mental disorders 
Out of the 74 participants with CMDs, 70 (94.5%) reported to have experienced at least one 
barrier to ART adherence in the previous month, whereas of the 149 participants without 
CMDs, only 100 (67.1%) reported at least one barrier to ART adherence in the previous month. 
The difference in proportion was statistically significant (χ2=20.6; p=<0.001). 
The barriers most reported by participants with CMDs include ‘forgetting’ (67.6%), ‘thinking 
too much’ (48.7%), ‘had to take the medications them in front of others’ (40.5%) and ‘not 
having a reminder’ (39.2%) (See Table 6). The top barriers for participants without CMDs were 
‘forgetting’ (29.5%), ‘not having the medications with them’ (21.5%), ‘not want others to 
know their status’ (20.2%) and ‘not having a reminder’ (19.5%). Although ‘forgetting’ and ‘not 
having a reminder’ were among the top barriers in both groups, the frequency with which 
they were reported varied greatly.  
The number of barriers reporting among participants with and without a CMD is presented 
graphically in Figure 7. The Mann Whitney U test showed that there is a significant difference 
(U=-7.209, p<0.001) between the number of barriers of participants with and without CMDs: 
participants with a CMD reported a greater number of barriers (median (md)=5, IQR=3-7) 
compared to those without CMDs (md= 1, IQR=0-4). 
 
Figure 7: Box plot showing the interquartile range of number of barriers to ART adherence for 
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A significant difference was also found in total BARTA scores between participants with and 
without CMDs: participants with a CMD reported a greater BARTA score (md=7, IQR=4-12) 
compared to those without a CMD (see figure 8) (md= 2, IQR=0-4; U=-7.415, p<0.001). 
 
 
Figure 8: The box plot showing the interquartile range of the total BARTA scores (severity of 
barriers to ART adherence) for participants with and without common mental disorders 
 
Non-parametric tests, (Mann-Whitney U tests (for binary variables) and Kruskal Wallis tests 
(for variables with more than 2 categories) indicated that none of the demographic or HIV-
related variables were associated with the total BARTA scores as shown in Table 7. The 
presence of an SUD was, however. Participants with a SUDs reported a greater BARTA score 
(md=6, IQR=4-11) compared to those without a SUD (md= 2, IQR=0-6; U=4.456, p<0.001).   For 
this reason, only SUD was included in the negative binomial regression model, to control for 
the effect of SUD when assessing the relationship between CMD and total BARTA scores. Even 
when controlling for presence of SUD, there was a strong association between BARTA scores 
and presence of CMD: independent of the presence of SUD, participants who had a CMD had 
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Table 7: Association between HIV related factors, demographic factors, probable substance 
use disorders and barriers to ART adherence  
Variable 
Total BARTA score 
 
Univariate analysis  
Multivariate analysis 
Median IQR U or χ2 P value RR 95% CL P-value 
Gender        
Female 3 1-8 
0.462 0.644 
   
Male 3 1-6    
Age        
18-24 3 1-7 
-0.161 0.872 
   
25-29 4 0-8    





   
Vertical 3 1-7    
Unknown and 
declined to answer 
6 3-10 
   
Education        
Primary and less 4 3-7 
3.642 0.162 
   
Secondary 3 0-7    
Tertiary 4 0-10    
Orphan hood status        
Lost a father 2 1-5.5 
0.352 0.949 
   
Lost a mother 3.5 0-9    
Lost both 3 1-8    
Not an orphan 4 0-8    
Employment status        




   
Employed by someone 
part time  
4 3-7 
   
Self-employed 4 1-6    
unemployed 3.5 1-9    
Student 2 1-6    
Marital status        
Cohabiting 3 1-7 
1.162 0.762 
   
Divorced/ widowed/ 
separated 
4 0.5- 9.5 
   
Married 4 1-6    
single 3 1-7    
Disclosure status        
Yes 3 0-8 
-0.642 0.521 
   
No 3 1-7    
Substance Use         
Yes 6 4-11 
4.456 <0.001 
ref   
No 2 0-6 .54 .378- .775 0.001 







No 2 0-4 ref   
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CHAPTER 5: DISCUSSION 
This chapter discusses the findings of the study and begins with the main findings according 
to the objectives of the study. Findings on common barriers to antiretroviral therapy (ART) to 
adherence among emerging adults living with HIV are explained based on the Ecological 
model for health promotion. The chapter also highlights the impact of the study as well as 
some recommendations on the matter under investigation. Finally, the chapter outlines the 
general conclusions of the study. 
Overview of the main findings  
The first objective of this study was to examine the prevalence of probable common mental 
disorders (CMDs) among emerging adults living with HIV. The prevalence of probable CMDs 
(i.e. probable depression and/or probable anxiety) was high with 33.2% of the participants 
experiencing probable CMDs.  Specifically, 31.8% had depression and 16.1% had anxiety. 
The study aimed to describe the prevalence, type, number and severity (the total BARTA 
score) of barriers to ART adherence among emerging adults living with HIV with probable 
CMDs compared to those without probable CMDs. The findings were that the prevalence of 
barriers to ART adherence was higher among those with CMDs (94.5%) than those without 
CMDs (67.1%) and the difference was statistically significant (χ2=20.6; p=0.00).  Furthermore, 
those participants with CMDs reported a greater number of barriers with a median score (md) 
of 5 and interquartile range (IQR) of 1-7 vs (md=1, IQR=0-4). In addition, emerging adults with 
CMDs experienced barriers to ART adherence more severely (had greater total BARTA score) 
than those without CMDs (md=7, IQR=4-12) vs (md= 2, IQR=0-4; U=-7.415, p<0.001). 
Prevalence of Common mental disorders 
This is the first study to examine the prevalence of probable CMDs among emerging adults 
living with HIV in Zimbabwe. Previous studies in adults in Zimbabwe reported prevalence of 
CMDs among adults aged 18 and above (Abas et al., 2017; Chibanda, Cowan, et al., 2016).  
The study found a high rate of probable CMDs of 33.2% among emerging adults living with 
HIV. The high rate of probable CMDs in this current study could be due, in part, to high levels 
of unemployment, interpersonal and collective violence and economic hardship prevailing in 
the country (Lund et al., 2018). A high number (39.5%) of emerging adults in this current study 
were unemployed. Studies have demonstrated that being unemployed can be risk factor for 
CMDs (Diraditsile & Ontetse, 2017; Ngum et al., 2017). Another explanation for high rates of 
Page | 58  
 
probable CMDs could be a lack of treatment services for CMDs in HIV clinics. During the time 
of data collection, the study site was not screening for CMDs, which limits identification and 
appropriate treatment of CMDs.  
The prevalence of CMDs found in this study is lower than what has been found in a study that 
was conducted among adults aged 18 and above in Zimbabwe where the prevalence of CMDs 
among adults living with HIV was 68.7% (Chibanda, Cowan, et al., 2016). The difference could 
be due to different tools that were used to determine the prevalence of CMDs. The prior study 
used the Shona Symptom Questionnaire-14 (SSQ-14) while this current study determined the 
prevalence of CMDs by combining tools; i.e. Patient Health Questionnaire-9 (PHQ-9) for 
probable depression and Generalized Anxiety Disorder -7 (GAD-7). Also, the current study did 
not include individuals aged 30 years and above while the prior study included them.  
In this study, probable CMDs were defined as having probable depression and/or anxiety. As 
reported in Chapter 2, I found that there were limited studies that focused on the prevalence 
of CMDs specifically among emerging adults living with HIV in both low and middle income 
countries (LMICs) and high income countries (HIC). Studies with similar populations focused 
either on depression or anxiety or both but presented the prevalence separately. (Dow et al., 
2016; Olagunju et al., 2012). The absence of studies (with similar samples) that provided the 
prevalence of combined depression and anxiety (i.e. CMDs) makes it difficult to compare the 
findings of this study with other studies. Hence, the sub-sections below compare the findings 
of this study on anxiety and pure depression with the findings from other studies with a 
similar age group in both HIC and LMICs.  
Prevalence of probable depression 
This study found the prevalence of probable depression among emerging adults living with 
HIV to be 31.8%. This high rate of probable depression among this population could be linked 
to some psychosocial stressors associated with living with HIV. In this study, the majority of 
the sample acquired HIV through vertical transmission (64.6%). Unlike emerging adults who 
acquired HIV through behavioural transmission, emerging adults who were born HIV positive 
are more likely to have been exposed to unfavourable childhood experience such as parental 
HIV/AIDS related illness and death (Cluver et al., 2015). In this study, the majority of the 
sample had lost at least one parent (75.3%). They could also have faced stressors such as 
disrupted schooling, being exploited by their caregivers, inadequate care, poverty and limited 
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social support, which may all contribute to the development of depression (Harms et al., 
2010). Furthermore, HIV related stigma, burden of taking ART everyday and frequent hospital 
visits all pose significant stress which could have contributed to high prevalence of depression 
among this population in this current study (Abebe et al., 2019; Mellins & Malee, 2013).  
Similar results have been found in a study which was conducted in Tanzania where 35.5% of 
individuals living with HIV aged 15 to 24 years had depression (Abebe et al., 2019). In contrast, 
a study from US reported a depression rate of 52.0% which was higher than what was found 
in this study  (Tanney et al., 2012). Other studies from England, USA, Tanzania, South Africa 
found rates that were lower than what was found in this current study and the rates were 
16%,15% 11.6%, 12.1% and 23.3% respectively (Cholera et al., 2017; Dow et al., 2016; Le 
Prevost et al., 2018; Martinez et al., 2009b; Shacham et al., 2017). The different rates could 
be attributed in part to differences in age and culture and the use of different tool to assess 
depression. 
Prevalence of anxiety 
Findings from this study were that 16.1% of the participants had probable anxiety. This rate 
could be linked to a number of reasons, such as engaging in romantic relationships, poverty 
and unemployment (Olagunju, Adeyemi, Ogbolu, & Campbell, 2012). One of the 
developmental tasks in emerging adulthood is the ability to form and maintain a healthy 
romantic relationship (Sussman & Arnett, 2014).. While forming healthy relationships may 
not be challenging for emerging adults with no chronic health conditions like HIV, this may 
pose anxiety for those who are living with HIV. Emerging adults may find it difficult to disclose 
their status due to fear of rejection, condom negotiation, public exposure, stigma and 
transmitting the disease to others (Shacham et al., 2012).  
The current high unemployment rate in Zimbabwe could have contributed to this high 
prevalence of anxiety in this study. As mentioned earlier the high number of emerging adults 
in this study were unemployed, while some were still at college. Emerging adulthood is a stage 
where people want to have a stable employment in order to secure their future and be able 
to contribute positively to their families and society (Arnett, 2015). Failure to get a job may 
lead to anxiety as they may fear of not having a bright future, or, if they get a job, they may 
face stigma and discrimination at the workplace because of their HIV status.  
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While there are limited studies that examined the prevalence of anxiety among emerging 
adults living with HIV,  results from this study are consistent with studies in both HICs and 
LMICs. A study conducted in US among 18 to 30 year old emerging adults living with HIV found 
the prevalence of anxiety to be 15.5% using the GAD-7 (Shacham et al., 2017). On the other 
hand, this study found rates for anxiety that were lower than reported in England (40%) 
among individuals living with HIV aged 13 to 21 years and USA (37,8%) among those aged 18 
to 34 years living with HIV (Le Prevost et al., 2018; Shacham et al., 2012). Cultural differences, 
use of different tools to assess anxiety and different sample could have contributed to the 
different rates.   
Barriers to ART adherence among emerging adults living with HIV 
This section describes findings on the prevalence, severity, number and common barriers to 
ART adherence among emerging adults living with HIV regardless of their mental health 
conditions.  
Prevalence, number and severity of barriers to ART adherence  
The prevalence, number and severity of barriers to ART adherence were investigated. Results 
from this study have shown that 76.2 % of the sample experienced at least one barrier to 
adherence and this is different from what has been reported in adults aged 18 years above in 
Zimbabwe, where 48% reported to have experienced at least one barrier to adherence.  This 
variation could be explained by the fact that this current study focused specifically on 
emerging adults aged 18 to 29 years who are at a developmental stage where risk taking is 
common while the other study from Zimbabwe included adults aged 18 and above and the 
majority of were aged above 29 years. Also a large number of emerging adults may be less 
likely to take their medication due to fear of being rejected by their friends compared to 
adults who may be more concerned about living longer in order to take care of their families.  
Findings from this study also indicated a higher prevalence of barriers to ART adherence 
among emerging adults than what has been found in a study that was conducted in US where 
47.2% of the individuals living with HIV aged 12 to 24 years reported to have experienced at 
least one barrier to ART adherence (Rudy et al., 2009). This difference could be attributed to 
different developmental stages of life. The sample in this study were individuals who are 
transitioning or have already transitioned into adult roles, while the study from USA were 
mainly adolescents. Emerging adults, especially those residing in an African country like 
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Zimbabwe face a number of challenges that may complicate their adherence including 
unemployment, financial instability and poverty. Having financial problems may make it 
difficult for emerging adults to go to the clinic to collect their medications. In addition, 
emerging adults are more likely to have less parental control than adolescents. Therefore, 
emerging adults may be more likely to report barriers to ART adherence than adolescents. 
The total score on the BARTA scale in this study indicated the severity of barriers to ART 
adherence. The results showed that the sample experienced severe barriers to ART 
adherence with the median (md) score of 3 and interquartile range (IQR) of 1-7. These results 
suggest that the primary care clinic should routinely screen for barriers to ART adherence. 
Common barriers to ART adherence among emerging adults living with HIV 
The COM-B model guided the results in this sub-section. The COM-B model of health 
promotion indicates that behaviour, for example, adhering to medication as prescribed) is 
determined by capability, opportunity and motivation (Ellis et al., 2019; Michie et al., 2011). 
In this study, emerging adults living with HIV reported 22 patient related barriers to ART 
adherence and they covered all the domains of COM-B (see Fig 6). As discussed in Chapter 2, 
the COM-B states that for a certain behaviour to be performed,  one must a) be physically and 
psychologically capable to perform it; b) have physical and psychological opportunities to do 
so; and c) be motivated to perform the behaviour (Michie et al., 2011). 
In this study factors such as forgetting, not being able to understand how and when to take 
the medications, and not understanding how the medication works influenced emerging 
adult’s capability to take their medications. Barriers to ART reported in this study that were 
grouped under opportunity include not having the medication, being busy, not wanting other 
people to know their HIV status and being asleep. Barriers to adherence, including tired of 
taking medication, feeling well and feeling sick, were categorised under motivation.    
‘Forgetting’ which can be categorised under psychological capability in the COM-B model was 
found to be the most common barrier to adherence. These results are in line with other 
studies carried out both in high and low and middle income countries, where forgetting was 
found to be among the top reasons for non-adherence to ART among PLWH (Croome et al., 
2017; MacDonell et al., 2013). Emerging adults may be trying to balance completing tertiary 
education, finding ways to earn a living in a harsh economy and at the same time trying to 
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take care of their extended families. Having a lot to do in a day may make emerging adults 
forget to take their medications.  
Closely related to this barrier is ‘not having a reminder’, a physical opportunity in the COM-B 
model, which was among the top barriers to ART adherence reported by this age group  Some 
people forget to take their medications if they do not have anyone or anything to remind 
them. Setting an alarm is a common way of reminding oneself to take medications. However, 
emerging adults who usually spend much of their time with their peers may avoid using this 
system as they may think that, if they peers continue hearing this alarm at the same time 
every day, they may suspect them of being HIV positive. Hence, they may opt not to make 
use of it. Some people living with HIV (PLWH) in Zimbabwe may make use of the support from 
their family members who may remind them to take their medication. This is however difficult 
for emerging adults who may be staying away from home as they will be at college or have 
relocated to some other areas due to employment. 
Findings of this study also confirm that emerging adults may not adhere to their HIV 
medications as they worry about stigma (Fields et al., 2017; MacDonell et al., 2013; Mutwa et 
al., 2013; Nabukeera-Barungi et al., 2015). Stigma can be grouped under social opportunity 
(Mcdonagh et al., 2018). While the Zimbabwean government and non-governmental 
organisations have put effort into reducing stigma by raising awareness, PLWH still face 
stigma and the disease has been associated with promiscuity (UNDP National AIDS Council of 
Zimbabwe, 2019). Emerging adults living with HIV usually do not disclose their HIV status to 
their peers, as they want to appear to be normal just like them and not to be labelled as being 
promiscuous. Due to this, when they are with other people they delay or skip their doses just 
to avoid being seen taking ART (Mutwa et al., 2013).  
Another barrier that was among the top barriers and that was common in both groups (with 
and without CMDs) was ‘not having the medication with them’ which can be categorised 
under physical opportunities. This finding echoes with findings from previous studies (Croome 
et al., 2017). A possible reason for this barrier could be travelling or being away from home 
where they store their medications. Due to fear of unintended disclosure and public exposure, 
emerging adults may opt to take their medications inside their homes only and may be 
unwilling to take their drugs outside their homes. 









Figure 6: Explaining barriers to adherence using COM-B adapted from (Michie et al., 2011) 
Capability 
Psychological  
• did not fully understand how or when to take them 
• Forgot 
• did not fully understand how they work 
Physical 
• did not have enough food to eat 





• did not want people to know my status 
• I had to take them in front of others 
• Fear of stigma 
Physical opportunities 
• I did not have them with me 
• did not have a reminder 
• change in my daily routine 
• was busy 








• Tired of taking my pills  
• Feeling well  
• Felt sick or ill 
• Worried about the long term effects of my medicines  
• Worried about them interacting with other medication 
I have to take  
• my religious or spiritual beliefs  
• I did not believe they were important for my current 
health  
• Felt they were harmful 
• Fear of side effects 
Automatic 
• was thinking too much or felt stressed 
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Common mental disorders and barriers to ART adherence among emerging adults 
living with HIV  
This section describes findings of this study on barriers to ART adherence among emerging 
adults living with HIV and CMDs in comparison to those without CMDs. To my knowledge, this 
is the first study to describe common barriers and the prevalence, number and severity of 
barriers to ART adherence among emerging adults living with HIV with CMDs in comparison 
to those without CMDs. 
Common barriers to ART adherence and common mental disorders 
The strength of this study is that it examined the barriers to ART adherence that are specific 
to emerging adults living with HIV with CMDs. In the analysis, findings were that only 
emerging adults with CMDs included ‘thinking too much’ among their top barriers.  Thinking 
too much is one of the symptoms of CMDs which can make it difficult for PLWH to take their 
medications as prescribed (Kidia et al., 2015b).  ‘Thinking too much’ among this age group, 
particularly in Zimbabwe, could have be triggered by stressors, such as unemployment, 
disclosing their status especially to their partners and fear of stigma. ‘Thinking too much’ 
could make it hard for emerging adults living with HIV with CMDs to concentrate, thereby 
forgetting to take their medications on time (Kidia et al., 2015b). 
Although ‘forgetting’ was a top barrier in both groups, it was more frequently reported among 
emerging adults with CMDs (67.6%) than those without CMDs (29.5%).  In addition, ‘not 
having a reminder’ was more frequently reported by those with CMDs (39.2%) than those 
without CMDs (19.5%). This could be because as explained in previous chapters CMDs, 
particularly depression may affect attention to specific tasks which may result in impaired 
memory recall thereby making one forget to take their medications (Kidia et al., 2015b; 
Wagner et al., 2011).  
Although not among the top barriers, alcohol use was reported more frequently among 
emerging adults with CMDs (16.2%) than those without (6.7%).  These findings are similar to 
a study that was conducted in Australia where they found that emerging adults with 
symptoms of depression and anxiety were at higher risk of alcohol abuse or dependence than 
those without depression and anxiety (Mckenzie et al., 2011). The use of alcohol among 
emerging adults living with HIV and CMDs in Zimbabwe can be regarded as a coping strategy 
to stressors such as being unemployed and HIV related stigma. Unemployed emerging adults 
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with CMDs may opt to hang around with friends while using alcohol rather than spending the 
day at home being idle. Moreover, they use alcohol as a way of dealing with the shame of 
failing to contribute financially for their families. The use of alcohol may complicate 
adherence as alcohol impairs judgment and decision making which may make one forget to 
take medication on time (Durvasula & Miller, 2015).   
Common mental disorders and prevalence, number and severity of barriers to ART 
adherence  
The prevalence of emerging adults living with HIV who reported to have experienced at least 
one barrier to ART adherence in the previous month was higher among those with CMDs 
(94.5%) than those without CMDs (67.1%).  
This study found a significant difference in the severity of barriers to ART adherence between 
emerging adults living with HIV with and without CMDs.  Emerging adults living with HIV and 
suffering from CMDs experienced more severe levels of barriers to ART adherence (md=7, 
IQR=4-12) compared to those without a CMD (see figure 8) (md= 2, IQR=0-4; U=-7.415, 
p<0.001). Confounding factors including gender, age, mode of transmission, education, 
orphan hood status, marital status, and disclosure were not associated with severity of 
barriers to ART adherence except for substance use disorders (SUDs). After I controlled for 
presence of SUDs, Ifound that there was a strong association between the severity barriers to 
ART adherence and CMDs, and emerging adults with CMD had 2.56 times the risk of 
experiencing severe levels of barriers to ART adherence compared to those without a CMD 
(IRR=2.56; p<0.001). The greater number and severity of barriers to ART adherence among 
emerging adults with CMDs compared to those without CMDs may be linked to the 
impairment caused by  some of the symptoms of depression. The symptoms of depression 
can affect many areas such as concentration, judgement, memory and problem solving that 
are necessary when one is taking medications (Kidia et al., 2015a). This may contribute to 
experiencing a greater number of barriers to ART adherence and more severely. For instance, 
symptoms of depression may impair problem solving, which may results in one failing to 
identify and solve some of the factors that hinder adherence. In addition, memory 
impairment and poor judgement may result in one forgetting to take their medication and 
abuse alcohol respectively. This further suggests that interventions that aim to improve 
barriers to ART adherence and adherence to ART should consider treating CMDs.  
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Limitations of the study 
This study utilised a cross sectional design hence causality cannot be inferred. This makes it 
difficult to conclude whether having a common mental disorder contributes to experiencing 
barriers to ART adherence, or experiencing barriers leads to CMDs. 
Another limitation is that this study did not measure adherence or address the relationship 
between CMDs and non-adherence. This is because firstly the study did not have sufficient 
funds and time to measure adherence using viral load monitoring which is the preferred 
method of measuring ART adherence (WHO, 2013). While the viral load testing is routinely 
collected in some HIV clinics in low-income countries, some of the results are not updated 
due to the delays in receiving the results from the laboratories. Hence studies usually conduct 
viral load testing on their own in order to make use of most recent viral load results (Abas et 
al., 2017; Phillips et al., 2016). The study could have utilised other methods for measuring 
adherence such as self-report but self-reports are associated with self-presentation and recall 
bias (Williams et al., 2013). Secondly, this study’s primary aim was to describe barriers to ART 
adherence in emerging adults living with HIV with probable common mental disorders (i.e. 
depression and/or anxiety) compared to emerging adults living with HIV without probable 
common mental disorders. Hence, measuring adherence and addressing the relationship 
between CMDs and non-adherence was beyond the scope of the current study. 
Also, the study was conducted in one HIV clinic in Harare.  Considering that the study was 
conducted at a referral clinic where most patients referred there present with serious 
conditions, findings of this study could have been overestimated, for example, the prevalence 
of probable depression. This makes it difficult to generalise these results to primary care 
clinics. Also the hospital is located in an urban area making it difficult to generalise to 
emerging adults in rural areas.  However, these results can be generalised to other referral 
hospitals in Zimbabwe such as Harare Hospital, Mpilo Hospital and Chitungwiza General 
Hospital. Considering that there are no such studies in Zimbabwe that focused on emerging 
adults, the results in the study may be a point of reference on the prevalence of CMDs and 
challenges that are being faced by emerging adults when taking their ART.  Furthermore, the 
findings from this study may be useful to inform the development of an intervention and to 
guide future research.  
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The study recruited participants using simple random sampling. While this could have 
minimised selection bias, the study relied on patients who had clinic appointments which 
could be have potentially excluded emerging adults with missed appointments. Excluding 
emerging adults with missed appointments could have underestimated the outcomes on 
barriers to ART adherence and the prevalence of probable CMDs.   
As this study relied on screening and not diagnostic tools to determine the prevalence of 
CMDs, the prevalence of CMDs could have been either underestimated or overestimated. 
However, the tools that have been used in this study were validated in Zimbabwe among 
adults and were translated into the local languages with a sensitivity of 85% and specificity of 
69% against a Structured Clinical Interview SCID diagnosis of depression (Cronbach α=0.86)  
(Abas et al., 2017; Chibanda, Cowan, et al., 2016; Croome et al., 2018).  The use of a validated 
tool increased the chances for this study to produce reliable and valid  results. 
While a validated tool was used to screen for barriers to ART adherence, it was validated 
among those aged 18 years and above including those aged 29 years and above. The use of 
this tool could have potentially eliminated barriers that are more specific for this particular 
age group.  Moreover, the tool consisted of patient-related barriers only, yet according to the 
ecological model for health promotion, adherence cannot be affected by patient related 
barriers only but by other factors such as structural barriers (e.g. lack of social support, poor 
relations with service providers, interpersonal and collective violence and peer influence) and 
interpersonal barriers (e.g.  lack of fund for transportation, inadequate healthcare service) 
(Bronfenbrenner, 1977; Lund et al., 2018; McLeroy et al., 1988).  
Lastly, this study did not address interpersonal and collective violence experienced by the 
participants, and especially gender differences, as a factor that could be a barrier to 
adherence. For example, a woman may not want to take her medication that reminds her 
partner of her and, possibly, his HIV status.  Lund et al (2018) showed that interpersonal and 
collective violence is one of the social determinants of mental disorders. The findings showed 
no gender differences in barriers to ART adherence and the BARTA may not have captured 
such a barrier.  
Potential Impact of the research 
Despite the limitations, the findings from this study offer valuable information for those 
working with emerging adults living with HIV. This novel study provides a starting point for 
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understanding barriers to ART adherence in emerging adults living with HIV in comparison to 
those without CMDs.  This study demonstrated that CMDs and barriers to ART adherence are 
highly prevalent among emerging adults living with HIV. Further, it showed that there is a 
relationship between CMDs and barriers to ART adherence. Emerging adults with CMDs 
experienced more barriers to ART adherence than those without CMDs. Although the results 
cannot be generalised, the findings underscore the need for routine screening for CMDs and 
barriers to ART adherence. Furthermore, they may help to guide the development of 
interventions that treat mental disorders and reduce barriers to ART adherence 
simultaneously as discussed earlier.  
Recommendations 
The recommendations are provided in relation to researchers, service providers, emerging 
adults with HIV and policy makers.  
Researchers 
This study utilised a cross sectional design and was conducted at a single clinic in Harare. As 
such, the results are difficult to generalise and unable to infer causality. Hence, there is need 
for future studies on this particular topic to be conducted in other setting like rural settings 
and use a different research design, for example longitudinal studies, and possibly some 
qualitative studies to understand these barriers further. 
Moreover, this study focused on prevalence of probable depression and anxiety as well as 
comparing the barriers to ART adherence between emerging adults with and without CMDs. 
Further studies are needed to examine the prevalence of other mental disorders that may be 
common among emerging adults, such as Posttraumatic stress disorders, and examine their 
association with barriers to ART adherence. Future studies are encouraged to examine the 
relationship of PTSD with barriers to ART adherence. This is important as it may guide future 
studies to come up with necessary interventions. This current study has laid the groundwork 
as it demonstrated that CMDs are prevalent among emerging adults living with HIV. 
Moreover, the study has shown that emerging adults living with HIV with CMDs experienced 
multiple barriers to ART adherence and were more likely to experience severe levels of 
barriers to ART adherence than those without CMDs. The next step is to come up with an 
evidence-based intervention focused on CMDs and barriers to ART adherence simultaneously 
among emerging adults living with HIV.  
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Several psychological interventions have proven to work in SSA including problem-solving 
therapy that has been piloted in Zimbabwe for treating depression and poor adherence 
among adults aged 18 years and above (Abas et al., 2017). Although this therapy may work 
for emerging adults, this study recommends an intervention tailored for this particular age 
group experiencing CMDs and barriers to ART adherence. In Zimbabwe, there is a program 
for emerging adults living with mental health problems and who are at risk of poor adherence 
(Abas et al., 2018). The program involves a combination of creative arts activities (including 
drama, music, dance and relaxation techniques), adherence counselling and income 
generating projects, which aimed to improve mental health, adherence to ART and livelihood. 
A randomised trial needs to be conducted to test for effectiveness of such an intervention for 
engaging emerging adults struggling with CMDs and barriers to ART adherence in order to 
improve mental wellbeing and adherence to ART medication.   
As stated in the limitations, this study did not measure adherence and address the 
relationship between non-adherence and CMDs among emerging adults living with HIV.  
Therefore, future studies are encouraged to examine the relationship between non-
adherence and CMDs among emerging adults living with HIV. Findings from the future studies 
will expand upon findings from the current study to understand how CMDs affect adherence 
to ART among emerging adults. This will also contribute to developing interventions that treat 
CMDs and non-adherence simultaneously among this population. 
Service providers and primary care clinics 
Since CMDs are associated with barriers to ART adherence, firstly, I would like to recommend 
routine screening for probable CMDs. There are tools that have been validated in Zimbabwe 
that can be used to screen for CMDs including the Shona Symptom Questionnaire-14 (SSQ-
14), PHQ-9 and GAD-7.  Screening for probable CMDs helps to identify individuals who are at 
risk of developing anxiety and depression and those who may meet the clinical criteria for 
these disorders.  Screening may also help to prevent and treat these CMDs. 
Routine screening for barriers to ART adherence is also recommended. The BARTA scale is a 
tool that has been recently developed in Zimbabwe, which can be used in clinics to identify 
these barriers to ART adherence. Again early identification of barriers to ART adherence may 
promote early intervention and improved adherence to ART. 
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Emerging adults living with HIV 
All emerging adults living with HIV are encouraged to communicate with their service 
providers during the early stages of facing difficulties when taking medications. Failure to take 
ART as recommended by the service providers may lead to high viral load, which may 
contribute to treatment failure and opportunistic infections. If barriers to ART adherence 
were to be identified at an early stage, it might allow early intervention before their viral load 
increases. 
Policy makers 
Findings of the study add to the increasing evidence that CMDs are prevalent among emerging 
adults living with HIV. These findings alone cannot improve the screening and management 
of CMDs among emerging adults living with HIV.  This study has also demonstrated that 
barriers to ART adherence are prevalent among this age group and those with CMDs are at 
an increased risk of experiencing barriers to ART adherence. Both barriers to ART adherence 
and CMDs have been found to be risk factors for non-adherence in previous studies. The 
Ministry of health (MoH) needs to ensure that all HIV primary care clinics raise awareness of 
CMDs and routinely screen for CMDs and barriers to ART adherence among emerging adults. 
Routine screening will promote early recognition of CMDs thus early intervention can occur. 
Also, if healthcare providers identify barriers to ART adherence early and address them in an 
effective way, this may assist to improve adherence to ART among this vulnerable population.  
Conclusions 
Common mental disorders and experiencing barriers to ART adherence are prevalent among 
emerging adults living with HIV. This study has shown that HIV infected emerging adults 
experience more barriers to ART adherence than those without CMDs. Prior research provides 
evidence that treating mental disorders will not only improve mental health functioning but 
also improve ART adherence and ultimately improve health and quality of life (Pence, 2009). 
There is a need to come up with tailored psychological interventions that can simultaneously 
treat CMDs and reduce barriers to ART adherence among emerging adults living with HIV. 
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Appendix A: Screening 
Screening log  
ID Date Sex Date of birth and 
age 
If excluded state 
reason: 
1. Below 18 
years 
2. Above 29 
years 
3. Too ill 
4. Did not sign 
consent 
State other reason 
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Appendix B: Demographic and HIV related variables 
Instructions 
Mirairo 
Answer the following questions; please provide one answer for each question.  
Pindurai mibvunzo inotevera; ndapota ipa mhinduro imwechete pamubvunzo wega-wega. 
Part A: Demographic Data 
When were you born?  
Makazvarwa riinhi? 
________________________________________________________ 
i. Orphanhood status: 
Are both of parents alive? 
Vabereki venyu vose vapenyu here? 
a. Yes they are both alive (Not orphan)  
Hongu vese vapenyu (havasi nherera) 
b. Lost a Mother  
Amai vakashaya 
c. Lost a Father  
Baba vakashaya 
d. Lost Both  
Vabereki vose vakashaya 
 
ii. Highest level of education: 
What is your highest level of education? 
Makadzidza kusvika papi? 
a. Did not attend school  
Hamuna kuenda kuchikoro 
b. Did not complete primary school  
Hamuna kupedza chikoro chevadiki 
c. Completed primary school only 
Makapedza chikoro chavadiki chete 
d. Did not complete secondary school 
Hamuna kupedza chikoro chavakuru  
e. Completed ordinary level only 
Makapedza danho rechina rechikoro chavakuru 
f. Did not complete high school  
Hamuna kupedza danho retanhatu kuchikoro chavakuru 
g. Completed advanced level only 
Makapedza danho retanhatu kuchikoro chavakuru 
h. Did not complete tertiary level 
Hamuna kupedza kukoreji 
i. Completed tertiary 
Makapedza kukoreji 
 
iii. Employment status 
What is your current employment status? 
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c. Self employed 
Munozvishandisa 
d. Employed by someone part time  
Munoshandira mumwe munhu dzimwe nguva 
e. Employed by someone full time 
Munoshandira mumwe munhu nguva dzose 
iv. Marital status 
What is your current marital status? 
Pari zvino makawanikwa here 
a. Single/Never married 
Hamusati mawanikwa 
b. Cohabiting 







Part B: HIV related variables  
i. Why are you here at the clinic? 
Sei muri pano pachipatara? 
 
___________________________________________________________________________ 
ii. Are you aware of your HIV status?  Yes  No 
Munoziva here zvamuri panyaya yeHIV? Houngu Kwete 
 
If No skip item ii, iii and iv – go to v 
If yes ask item ii, 
 
iii. How do you think you got infected?  
Munofunga kuti makawana sei hutachiwana hweHIV? 
a. Vertically – I was born with it 
Kuzvarwa nehutachiwana 
b. Behaviourally – 1. through having unprotected sexual intercourse  
Nekuita bonde risina dzivirirwa 
2. Injection drug use  
Kushandisa tsono dzinoshandiswa pakushandisa zvinodhaka 
3. Blood transfusion  
kuwedzerwa ropa 
c. I do not know 
Hamuzive 
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d. Or other means (specify) ___________________________________________________ 
Nedzimwewo nzira (tsanangurai) 
iv. Have you disclosed your status to anyone? Yes        No 
Pane wamakambotaurira here kuti mune hutachiwana hweHIV?  Hongu   Kwete 
v. If yes, who did you disclose it to? _____________________________________(write person’s 
relationship to you – not their name) 
Kana mati hongu, ndiani wamakazivisa (taurai hukama hwenyu- kwete zita ravo) 
vi. Are you on ART medication?   Yes  No 
Muri pamushonga weART here? Hongu Kwete 
vii. Date initiated ART___________________________________________________________ 
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Appendix C: Barriers to ART adherence 
 
Taking HIV medicines every day is really difficult. Most people have problems taking their medicines at some 
point during treatment for a variety of reasons. Some people skip taking their medicines or often take it later than 
the target time. Here is a list of possible reasons why some people have skipped or delayed taking their HIV 
medicines. For each reason please say if you did not take all of your HIV medicines on time in the past month 
always, most of the time, some of the time, rarely or never.  
Kutora mushonga weHIV mazuva ose kwakaoma. Vanhu vazhinji vanosangana nematambudziko dzimwe nguva 
pakunwa kwavanoita mushonga nekuda kwezvikonzero zvakasiyana-siyana. Vamwe vanokanganwa kunwa 
mishonga yavo kana kuzonwa nguva inotarisirwa kunwa yapfuura.  Izvi ndizvo zvikonzero zvinogona kuita kuti 
vamwe vanhu vakanganwe kana kunonoka kunwa mishonga. Pachikonzero chega chega ndapota taurai kana 
musina kunwa mishonga yenyu yese yeHIV nenguva mumwedzi wapfuura, nguva dzose, dzimwe nguva, kashoma 
kuiitika kana kuti hazviitike  
 
 Question 
 I did not take all of my HIV 
medicines on time because .... 
Handina kunwa mishonga yangu 



















1 Of my religious or spiritual beliefs  
Nekuda kwezvitendero zvekunamata kana 
zvitendero zvechivanhu 
     
2 I did not believe they were important for my 
current health 
nekuti ndaisatenda kuti yakakosha 
pautano hwangu hwaiye zvino 
     
3 I did not fully understand how or when to 
take them 
Nekuti handina kunzwisisa kuti unonwiwa 
sei kana kuti unonwiwa nguvai 
     
4 I did not want people to know my status 
Nekuti ndaisada kuti vanhu vazive 
pandimire  
     
5 of side effects 
nekuda kwematambudziko andaizogona 
kusangana nawo kana ndabva kumanwa 
(side effects) 
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 Question 
 I did not take all of my HIV 
medicines on time because .... 
Handina kunwa mishonga yangu 



















6 I was worried about the long term effects of 
my medicines 
 
Nekuti ndainetsekana nezvaizogona 
kuitika nekuda kwemushonga uyu 
nekufamba kwenguva 
     
7 I felt they were harmful 
Nekuti ndaifunga kuti inokuvadza 
     
8 I did not have a reminder 
Nekuti ndanga ndisina chinondiyeuchidza 
     
9 I forgot 
Nekuti ndakakanganwa 
     
10 I was asleep when I was supposed to take 
them 
Nekuti ndanga ndakakotsira pandaifanirwa 
kuinwa 
     
11 I did not have them with me 
Nekuti ndanga ndisinawo pandiri 
     
12 I felt sick or ill 
Nekuti ndairwara 
     
13 I was thinking too much or felt stressed 
Nekuti ndaifungisisa kana kuti 
ndaishungurudzika 
     
14 I was feeling well 
nekuti ndainzwa zvakanaka 
     
15 I did not fully understand how they work 
Nekuti ndanga ndisina kunyatsonzwisisa 
kuti anoshanda sei 
     
16 I was tired of taking my pills 
Nekuti ndanga ndaneta nekunwa mapiritsi 
angu 
     
17 I was busy 
Nekuti ndanga ndakabatikana ndichiita 
zvimwe zvinhu. 
     
18 I had to take them in front of others 
Nekuti ndaifanirwa kuinwa pamberi  
pevamwe 
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 Question 
 I did not take all of my HIV 
medicines on time because .... 
Handina kunwa mishonga yangu 



















19 I was worried about them interacting with 
other medication I have to take 
Nekuti ndaitya kukanganisa kushanda 
kwemimwe mishonga yandinofanira 
kunwa 
     
20 Of a change in my daily routine 
Nekuda kwechiitiko chakaitika chakange 
chisina kutarisirwa chikakanganisa 
zvandinosiita mazuva ose 
     
21 I did not have enough food to eat 
Nekuti ndanga ndisina chikafu chakakwana 
chekudya 











I was drinking alcohol 
Nekuti ndainwa doro 
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Appendix D:Patient Health Questionnaire-9 (PHQ-9) 
Instructions 
Please circle on the appropriate number response 
Over the LAST 2 WEEKS, how often have you been bothered by 
any of the following problems? 
Mumasvondo maviri apfuura makashungurudzwa  kangani 
nematambudziko anotevera 

















1 Little interest or pleasure in doing things. 
Kusanyatsova nechido chekuita zvinhu 
0 1 2 3 
2 Feeling down, depressed, or hopeless. 
Kusanyatsonzwa chido nezvehupenyu, kufunganya 
zvakapfuurikidza kana kushaya tariro muhupenyu 
0 1 2 3 
3 Trouble falling or staying asleep, or sleeping too much. 
Kutadza kuwana hope kana kurara zvakapfuurikidza 
0 1 2 3 
4 Feeling tired or having little energy. 
Kunzwa kuneta uye kuve nesimba shoma rekuita zvinhu 
0 1 2 3 
5 Poor appetite or overeating. 
Kusanyatsodya zvakakwana kana kudyisa 
0 1 2 3 
6 Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down. 
Kuzvizvidza pachezvako-kana kuti kunzwa sekuti 
urimukundikani muhupenyu  kana kutadza kuzadzikisa 
zvaitarisirwa nevemhuri yako 
0 1 2 3 
7 Trouble concentrating on things, such as reading the 
newspaper or watching television.Kutadza kuita zvinhu 
0 1 2 3 
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zvakaita sekuverenga pepanhau nekuona chivhitivhiti 
pfungwa dziri pamwechete 
8 Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless 
that you have been moving around a lot more than usual. 
Kufamba kana kutaura zvine kunonokera mukati zvekuti 
zvinogona zvakaonekwa nevamwe vakakutenderedza? 
Kana kuti kutadza kugarisika zvekuti wange urikufamba-
famba zvakapfuurikidza zvaunofanirwa kunge uchiita 
0 1 2 3 
9 Thoughts that you would be better off dead or of hurting 
yourself in some way. 
Kuve nendangariro dzekuti zvirinani kuti dai wafa 
zvakodu kana kuda kuzvikuvadza neimwe nzira 
0 1 2 3 
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Appendix E: GAD-7 
Over the last 2 weeks, how often have you been bothered by any of 
the following problems?  

































Feeling nervous, anxious or on edge.  




 1  2  3 
2 
Not being able to stop or control worrying.  




 1  2  3 
3 
Worrying too much about different things. 
Kushushikana zvakanyanya nekuda 
kwezvinhu zvakasiyana- siyana 
 
0 
 1  2  3 
4 
Trouble relaxing. 
Kutadza kuzorora zvakanaka 
 
0 
 1  2  3 
5 
Being so restless that it is hard to sit still. 
Kushushikana zvekuti kugarisika kwainetsa 
 
0 
 1  2  3 
6 
Becoming easily annoyed or irritable. 
Kukurumidza kusvotwa nezvinhu 
 
0 
 1  2  3 
7 
Feeling afraid as if something awful might 
happen. 




 1  2  3 
  








A total of 5+ indicates increasing or higher risk drinking. 
Zvibodzwa zvishanu (5) zvichikwira zvinoratidza kuwedzera kana njodzi huru yekunwa. 
An overall total score of 5 or above is AUDIT-C positive. 
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Appendix G: Drug Use Disorders Identification Test (DUDIT) 
For each question select your answer and fill in the score given in the box at the end of the row 
 Question 0 1 2 3 4 Score 
1 How often do you use 
drugs other than 
alcohol? 
Munoshandisa zvimwe 




















4 times a week or 
more often 
Kaina pavhiki kana 
kakawanda 
 
2 Do you use more than 
one type of the drug on 






















4 times a week or 
more often 
Kaina pavhiki kana 
kakawanda 
 
3 How many times do you 
take drugs on a typical 
day when you use drugs? 
Munoshandisa 
zvinodhaka kakawanda 
sei muzuva rimwechete? 
0 1-2 3-4 5-6 7 or more  
4 How often you are 








Less often than 














5 Over the past year, have 
you felt that your longing 
for drugs was so strong 











Less often than 















6 Has it happened, over 
the past year that you 
have not been able to 
stop taking drugs once 




Less often than 
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Zvakamboitika here 





7 How often over the past 
year have you taken 
drugs and then neglected 
to do something you 
should have done? 
Mugore rapfuura, 
zvakaitika kakawanda 
sei kuti makashandisa 
zvinodhaka muchibva 






Less often than 















8 How often over the past 
year have you needed to 
take a drug the morning 
after heavy drug use the 
day before? 
Mugore rapfuura, 









Less often than 















9 How often over the past 
year have you had guilt 











Less often than 















10 Have you or anyone else 
hurt (mentally or 
physically) because you 
used drugs? 
Makambokuvara here 
kana kuti mumwe 
munhu (mupfungwa 




 Yes, but not 
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11 Has a relative or a friend, 
a doctor or a nurse or 
anyone else, has worried 
about your drug use or 
said to you that you 
should stop using drugs? 
Pane here wehukama, 
kana shamwari, kana 











 Yes, but not 
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Appendix H: English Informed Consent form 
Informed Consent form 
Common Mental Disorders, Substance Use Disorders and barriers to ART 
adherence among young adults living with HIV 
Principle Investigator: Ms Emily Saruchera 
Supervisors: Dr. Marguerite Schneider, Dr. Melanie Abas, Dr. 
Munyaradzi Madhombiro 




You are being invited to take part in this study entitled Common Mental Disorders, substance 
use disorders and barriers to ART adherence in young adults aged 18 to 29 years. The research 
study is being conducted at Parirenyatwa Centre of Excellence by Ms Emily Saruchera, a 
student at University of Cape Town and her supervisors are Dr. Marguerite Schneider, Dr. 
Melanie Abas, and Dr. Munyaradzi Madhombiro. This research study is being sponsored by 
the African Mental Health Research Initiative.  
It is important for you to read and understand why this research study is being conducted and 
what it also involves before you decide to take part. Please read all the information provided 
below and feel free to ask any questions to the researcher if you need clarity. If you agree to 
take part in this study you will be asked to sign this consent form and you will be offered a 
copy to keep. 
Purpose  
The purpose of this study is to find out how many young adults living with HIV at a clinic in 
Harare experience depression, anxiety, post-traumatic stress disorder and substance use 
disorders. It will further examine the relationship of depression, anxiety, post-traumatic stress 
disorder and substance use disorders with barriers to antiretroviral therapy adherence in 
young adults living with HIV. Previous studies carried in Zimbabwe have shown that there are 
high rates of common mental and substance use disorders in older adults living with HIV. They 
have also shown that common mental disorders may affect how patients (older adults) take 
their medication. However, very few studies in Zimbabwe have looked at the prevalence of 
depression, anxiety, post-traumatic stress disorder, substance use disorders and its 
association with barriers to ART adherence in young adults living with HIV. This study would 
also like to find out to what extent young adults living with HIV also experience depression, 
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anxiety, post-traumatic stress disorder and substance use disorders and how these may be 
related to barriers to ART adherence. 
Participants 
This study seeks young males and females aged 18 to 29 years who access HIV treatment at 
Parirenyatwa Centre of Excellence. If you are below the age of 18, above the age of 29 years 
and too unwell physically and mentally then unfortunately you are not eligible to participate 
in this study. 
Procedure and Duration 
If you decide to participate in this study, you will undergo a survey questionnaire which will 
last between 25 to 40 minutes. The questionnaire will consist of questions about depression, 
anxiety, post-traumatic stress disorder, substance use disorders and barriers to ART 
medications. The questionnaire will be administered by a trained researcher. We will also 
check in your clinic book the date you were initiated on ART. 
Potential risks and Discomforts  
There will be minimal risk to you but you may find some of the questions make you feel 
emotional. We can talk about that if you do get such feelings. If you however, feel that you 
want to discontinue you are allowed to do so.  
Benefits  
You may not benefit directly from this study but it may guide future research, benefit the 
clinic as whole by identifying the prevalence of depression, anxiety, post-traumatic stress 
disorder, substance use disorders and its relationship with barriers to ART adherence.  It may 
benefit other patients in the future.  
Cost, compensation and reimbursements 
There will be no cost for you since the study will be done at the clinic. You will not be 
reimbursed for transport costs since you will only meet the researcher once when you come 
for your clinical appointments. However, if you fail to complete the questionnaire in one day, 
you may be asked to come back the next day and complete it. In that case you receive $3 to 
reimburse your transport costs. you will receive refreshments to compensate for the time you 
will spend participating in the study. 
Confidentiality 
If you decide to participate in this study, all information that you will provide will remain 
private and confidential. No third part will have access to the information. Confidentiality will 
only be breached if you are at risk of suicide or if you show symptoms of depression, anxiety, 
post-traumatic stress disorder and substance use disorders on the assessment tools we will 
be using. In such a case you will be referred to our treatment team which consist of a clinical 
psychologist, psychiatrist and physician for further assessment and consideration for 
treatment. In order to protect you, your name will not appear on the questionnaire or in any 
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reports of publications on the results and the details you will provide will not be traceable 
back to you.  
Voluntary Participation 
Your participation in this study is voluntary. You are also allowed to withdraw or discontinue 
from the study at anytime without stating the reason and without any penalty. You will also 
have an option of withdrawing with your data that you would have provided. 
Offer to answer Questions 
If you have any question or anything unclear to you related to this research study, please feel 
free to ask the researcher before you sign the consent form. For further information, you may 
contact Ms Emily Saruchera on +263 772 309 007. 
NOTE:  If you have any ethical complains of this study you may contact the Medical Research 
Council of Zimbabwe on telephone number +263 (4) 791792. 
Conflict of interest 
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CONSENT FORM 
Thank you very much for considering taking part in this study. If there is anything unclear from 
the information sheet please ask the researcher before you sign this consent form. You will 
have another copy of this information and consent form to keep. 
• I have read and understood all the information provided above
• I agree to take part in this research study voluntarily.
• I understand that I can withdraw from the study any time
• I consent having my date I initiated ART recorded from my clinic book
------------------------------------------------------------------------- -------------------------------------------- 












Page | 110  
 
Appendix I: Shona Informed Consent form 
 
  Gwaro rewirirano 
Common Mental Disorders, Substance Use Disorders and barriers to ART 
adherence among young adults living with HIV 
Mukuru wetsvakiridzo: Ms Emily Saruchera 
Supervisors: Dr. Marguerite Schneider, Dr. Melanie Abas, Dr. 
Munyaradzi Madhombiro 




Muri kukokwa kuti munge muri mutsvakairidzo inonzi matambudziko ekufungisisa, 
kushurudzika kana kushandisa zvinodhaka zvakapfuridza nezvinokanganisa kunwa mushonga 
we ART muvanhu vechidiki vari pakati pemakore makumi nesere (18) ne makumi maviri 
nepfumbamwe (29). Tsvakiridzo iyi iri kuitirwa paParirenyatwa Centre of Excellence 
namuzvare  Emily Saruchera uyo achange achifundiswa na chiremba Marguerite Schneider, 
chiremba Melanie Abas, uye chiremba Munyaradzi Madhombiro. Tsvakiridzo iyi iri 
kubhadharwa neve Africa Mental Health Research Initiative (AMARI).  
Musati maiita sarudzo yekuti munge muri mutsvakiridzo zvakakosha kuti muverenge 
pamwechete nekunzwisisa chinangwa chetsvakiridzo uye kuti ichange ichiita nezvei. Ndapota 
verengai mashoko ese akanyorwa pazasi uye sunungukai kubvunza mutsvakiridzi kana muine 
chero mubvunzo wamungade kuti ujekeswe. Kana muchinge mabvuma kuva mutsvakiridzo 
ino, muchakumbirwa kuti musaine gwaro rewirirano uye muchazopihwa gwaro renyu rekuti 
muchengeta. 
Chinangwa 
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Chinangwa chetsvakiridzo ino ndechekuda kunzwisisa kuti vanhu vechidiki vari kurarama 
nehutachiwana avo vanobatsirwa pakiriniki iri muHarare vanangani vavo vari kusangana 
nematambudziko ekufungisisa, kuzvidya moyo, kushungurudzika kwakanyanya mushure 
mekusangana nenjodzi nekushandisa zvinodhaka zvakapfuridza. Tsvakiridzo ino ichaongorora 
hukama huri pakati pematambudziko aya nezvingakanganisa kunwa mushonga weART 
muvanhu vechidiki vanorarama nehutachiwana hweHIV. Dzimwe tsvakiridzo dzakaitwa 
muZimbabwe dzakaratidza kuti vanhu vakuru vakawanda vanosangana nematambudziko ane 
chekuita nekufungisisa kana kushungurudzika uye nekushandisa zvinodhaka zvakapfurikidza. 
Tsvakiridzo idzi dzakaitwa muvanhu vakuru dzakaratidza zvakare kuti matambudziko iwaya 
ekufungisisa nekushungurudzika kuti anogona kukanganisa kunwa mishonga zvakanaka. 
Kunyangwe hazvo tsvakiridzo idzi dzakaitwa, dzishoma dzakaongorora hukama huri pakati 
pematambudziko ane chekuita nepfungwa anosanganisira kufungisisa, kuzvidya moyo, 
kushungurudzika kwakanyanya mushure mekusangana nenjodzi ,kushandisa zvinodhaka 
zvakapfuridza nezvinokanganisa kunwa mushonga weART muvanhu vechidiki vanorarama 
nehutachiwana hweHIV. Nekudaro tsvakiridzo iyi ichaongorora huwandu hwevanhu vachidiki 
vanosangana nematambudziko ekufungisisa, kuzvidya moyo, kushungurudzika kwakanyanya 
mushure mekusangana nenjodzi ,kushandisa zvinodhaka zvakapfuridza uye nekutarisa 
hukama hwematambudziko aya nezvinokanganisa kunwa mushonga weART zvakanaka. 
Vanhu vachange mutsvakiridzo 
Vanhu vachange vari mutsvakiridzo ino varume nevakadzi vechidiki vari pakati pemakore 
makumi nesere ne makore makumi maviri nemapfumbamwe vanorarama neutachiwana 
hweHIV vachirapwa pakiriniki inonzi Parirenyatwa Centre of Excellence. Kana muchinge 
musati masvika makore makumi nemasere kana kuti makadarika makore makumi maviri 
nepfumbamwe uye muri kurwara zvakanyanya  zvese muviri nemupfungwa tinourumbo 
hazvigone kuti munge muri mutsvakiridzo iyi. 
Zvichaitwa neNguva 
Kana muchinge masarudza kuva mutsvakiridzo ino, muchabvunzwa mibvunzo kwemaminitsi 
ari pakati pe makumi maviri nemashanu (25) ne makumi mana (40). Mibvunzo iyi ichange ine 
chekuti nekufungisisa, kuzvidya moyo, kushungurudzika kwakanyanya mushure 
mekusangana nenjodzi ,kushandisa zvinodhaka zvakapfuridza uye zvinokanganisa kunwa 
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mushonga weART zvakanaka. Muchange muchibvunzwa  nemutsvakiridzi akadzidziswa kuita 
izvi. Tichazenge zvakare tichitarisa mubhuku renyu remuchipatara kuti makatanga riinhi 
kunwa mishonga weART. Tinogona kukumbirai kuti muve muhurukuro ine chekuita 
nezvamakasangana nazvo kana muchinge makambosangana nezviitiko zvinokonzeresa 
trauma kumashure. Hurukuro iyi inogona kuiitika pakati pe awa rimwechete kana maviri. 
Tinozoronga kuti munge muchizodzoka kumusangano uyu nerimwe zuva. Kana muchinge 
mapinda muhurukuro iyi, muchange muchitapwa mazwi. 
Njodzi kana Matambudziko 
Hatitarisire kuti mungasangana nenjodzi yakanyanya asi munogona kubatikana nemimwe 
mibvunzo yamuchabvunzwa. Kana izvi zvichinge zvaitika kwamuri, tinogona kumbokurukura. 
Asi kana muchinge mafunga kubuda muchirongwa, munotenderwa henyu. 
Zvichawanikwa 
Munogona kusawana rubatsiro rwakanangana nemi asi tsvakiridzo iyi, inogona kuwana ruzivo 
rwungabatsidza tsvakiridzo dzangaitwa muna ramangwana zvakare inogona kubatsira kiriniki 
kuti izive huwandu hwe matambudziko ekufungisisa, kuzvidya moyo, kushungurudzika 
kwakanyanya mushure mekusangana nenjodzi ,kushandisa zvinodhaka zvakapfuridza uye 
nehukama hwematambudziko aya nezvinokanganisa kunwa mushonga weART zvakanaka. Izvi 
zvinogona kuzobatsira vamwe varwere mune ramangwana. 
Mubhadharo nemuripo 
Hapana chamunobhadhara sezvo tsvakiridzo ichange ichiitira pakiriniki. Muchange 
muchizosangana nemutsvakiridzi kamwechete apo pamunenge muuya kumisangano yenyu 
yamagara muchiuya kukiriniki, nekudaro vetsvakiridzo hakwanise kunge vachikupai muripo 
wekufambisa. Asi kana muchinge makundikana  kupindura mibvunzo yese muzuva 
rimwechete, kana kuti muchinge  mapinda muhurukuro yetrauma munokumbirwa kuti 
munge muchizodzoka pazuva ramunenge makasuninguka, kana muchinge madzoka 
muchazenge muchipihwa $3 yeripira muchovha. Muchange muchipihwa zvinwiwa kuripira 
nguva yenyu yamuchange muri mutsvakiridzo. 
Zvakavanzika 
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Kana muchinge masarudza kuva kutsvakiridzo iyi, zvese zvamuchatura zvinoramba 
zvakavanzika uye hakuna mumwewo munhu asiri mutsvakiridzi mutsvakiridzo ino anowana 
ruzivo rwamuchatipa. Kunze kwekuti maonekwa muine dambudziko rekufungisisa, kuzvidya 
moyo, kushungurudzika kwakanyanya mushure mekusangana nenjodzi ,kushandisa 
zvinodhaka tinoziva clinical psychologist kana psychiatrist kana vamwe vana chiremba kuitira 
kuti mubatsirwe padambudziko iroro. Kuti tikuchengetedzei, zita renyu harinyorwe pagwaro 
remubvunzo kana pane mashoko achashambidzwa zvekuti hakuna anoziva kuti mashoko 
amakataura ndeapi. 
Sarudzo yekuvamustvakiridzo 
Isarudzo yenyu kuva mutsvakiridzo ino, hamumanikidze. Makasununguka kubuda 
mutsakiridzo chero ipi nguva zvayo musina kupa chikonzero uye pasina mubhadharo. 
Munotenderwa zvakare kana muchida kutora mashoko kana ruzivo rwenyu rwamunenge 
mambopa kutsvakiridzo. 
Kana muine mibvunzo 
Kana muine mibvunzo kana chamusina kunzwisisa zvine chekuita netsvakiridzo, sunungukai 
kubvunza mutsvakiridzi musati masaina gwara rewirirano. Kana muchida kunzwa zvizire 
munogona kuchaira muzvare Emily Saruchera ruunhare panhamba dzinoti 0772309007.  
CHERECHEDZA: Kana muine zvichemo zvine chekuita nekodzero dzenyu, munokwanisa 
kuchaira runhare veMedical Research Council of Zimbabwe panhamba dzinoti +263 (4) 79179 
GWARO REWIRANO 
Tinokutendai zvikuru nekusarudza kuva mutsvakiridzo ino. Kana paine chamusina kunzwisisa 
pagwaro remashoko, ndapota bvunzai mutsvakiridzi musati masaina gwaro rewirirano. 
Muchapihwa gwaro renyu kuti mugochengeta. 
• Ndaverenga ndikanzwisisa mashoko ari pamusoro
• Ndazvisarudzira kuva mutsvakiridzo ino
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• Ndinonzwisisa kuti ndinogona kubuda mutsvakiridzo ino chero nguva
• Ndinobvuma kuti zuva randakatanga kunwa mushonga weART ritariswe mubhuku
rangu rekukiriniki
------------------------------------------------------------------------- -------------------------------------------- 
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signature removed to avoid exposure online
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